UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended SeptemberJune 30, 20212022.
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to .
Commission File Number 001-16537
ORASURE TECHNOLOGIES, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware |
| 36-4370966 |
(State or Other Jurisdiction of Incorporation or Organization) |
| (IRS Employer Identification No.) |
220 East First Street, Bethlehem, Pennsylvania |
| 18015 |
(Address of Principal Executive Offices) |
| (Zip code) |
Registrant’s telephone number, including area code: (610) 882-1820
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Common Stock, $0.000001 par value per share | OSUR | The NASDAQ Stock Market LLC |
Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☒ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |||
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by checkmark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of November 1, 2021,August 5, 2022, the registrant had 72,038,43972,619,055 shares of common stock, $.000001 par value per share, outstanding.
PART I. FINANCIAL INFORMATION
| Page |
Item 1. Financial Statements (Unaudited) | |
Consolidated Balance Sheets at | 3 |
4 | |
5 | |
6 | |
7 | |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations |
|
Item 3. Quantitative and Qualitative Disclosures About Market Risk |
|
| |
PART II. OTHER INFORMATION | |
| |
| |
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds |
|
| |
| |
| |
| |
|
Item 1. FINANCIAL STATEMENTS
ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Unaudited)
(in thousands, except per share amounts)
| September 30, 2021 |
|
| December 31, 2020 |
| June 30, 2022 |
|
| December 31, 2021 |
| ||||
ASSETS |
|
|
|
|
|
|
|
|
|
| ||||
Current Assets: |
|
|
|
|
|
|
|
|
|
| ||||
Cash and cash equivalents | $ | 134,962 |
|
| $ | 160,802 |
| $ | 66,159 |
|
| $ | 116,762 |
|
Short-term investments |
| 50,065 |
|
|
| 48,599 |
|
| 29,625 |
|
|
| 36,279 |
|
Accounts receivable, net of allowance for doubtful accounts of $4,891 and $3,654 |
| 40,075 |
|
|
| 38,835 |
| |||||||
Accounts receivable, net of allowance for doubtful accounts of $3,222 and $3,418 |
| 62,886 |
|
|
| 45,323 |
| |||||||
Inventories |
| 53,583 |
|
|
| 31,863 |
|
| 71,304 |
|
|
| 53,138 |
|
Prepaid expenses |
| 8,103 |
|
|
| 3,860 |
|
| 5,477 |
|
|
| 7,939 |
|
Other current assets |
| 2,439 |
|
|
| 4,934 |
|
| 31,855 |
|
|
| 28,990 |
|
Total current assets |
| 289,227 |
|
|
| 288,893 |
|
| 267,306 |
|
|
| 288,431 |
|
Noncurrent Assets: |
|
|
|
|
|
|
|
|
|
| ||||
Property, plant and equipment, net |
| 77,586 |
|
|
| 51,860 |
|
| 93,697 |
|
|
| 88,164 |
|
Operating right-of-use assets, net |
| 9,615 |
|
|
| 4,461 |
|
| 16,451 |
|
|
| 9,056 |
|
Finance right-of-use assets, net |
| 4,629 |
|
|
| 1,312 |
|
| 1,887 |
|
|
| 2,493 |
|
Intangible assets, net |
| 15,221 |
|
|
| 17,904 |
|
| 12,851 |
|
|
| 14,343 |
|
Goodwill |
| 40,264 |
|
|
| 40,351 |
|
| 36,038 |
|
|
| 40,279 |
|
Long-term investments |
| 17,271 |
|
|
| 47,718 |
|
| — |
|
|
| 17,009 |
|
Other noncurrent assets |
| 1,944 |
|
|
| 1,973 |
|
| 1,024 |
|
|
| 1,215 |
|
Total noncurrent assets |
| 166,530 |
|
|
| 165,579 |
|
| 161,948 |
|
|
| 172,559 |
|
TOTAL ASSETS | $ | 455,757 |
|
| $ | 454,472 |
| $ | 429,254 |
|
| $ | 460,990 |
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
|
| ||||
Current Liabilities: |
|
|
|
|
|
|
|
|
|
| ||||
Accounts payable | $ | 23,778 |
|
| $ | 17,407 |
| $ | 36,226 |
|
| $ | 28,024 |
|
Deferred revenue |
| 3,488 |
|
|
| 4,811 |
|
| 2,660 |
|
|
| 2,936 |
|
Accrued expenses and other current liabilities |
| 22,610 |
|
|
| 22,227 |
|
| 23,165 |
|
|
| 33,778 |
|
Finance lease liability |
| 1,912 |
|
|
| 517 |
| |||||||
Operating lease liability |
| 2,178 |
|
|
| 1,125 |
| |||||||
Finance lease liabilities |
| 1,182 |
|
|
| 939 |
| |||||||
Operating lease liabilities |
| 2,054 |
|
|
| 2,181 |
| |||||||
Acquisition-related contingent consideration obligation |
| 201 |
|
|
| 402 |
|
| 199 |
|
|
| 206 |
|
Total current liabilities |
| 54,167 |
|
|
| 46,489 |
|
| 65,486 |
|
|
| 68,064 |
|
Noncurrent Liabilities: |
|
|
|
|
|
|
|
|
|
| ||||
Finance lease liability |
| 2,834 |
|
|
| 895 |
| |||||||
Operating lease liability |
| 7,740 |
|
|
| 3,591 |
| |||||||
Finance lease liabilities |
| 1,445 |
|
|
| 1,952 |
| |||||||
Operating lease liabilities |
| 14,978 |
|
|
| 7,202 |
| |||||||
Acquisition-related contingent consideration obligation |
| 318 |
|
|
| 2,049 |
|
| 117 |
|
|
| 354 |
|
Other noncurrent liabilities |
| 1,998 |
|
|
| 1,682 |
|
| 489 |
|
|
| 651 |
|
Deferred income taxes |
| 880 |
|
|
| 1,195 |
|
| 2,547 |
|
|
| 2,234 |
|
Total noncurrent liabilities |
| 13,770 |
|
|
| 9,412 |
|
| 19,576 |
|
|
| 12,393 |
|
TOTAL LIABILITIES |
| 67,937 |
|
|
| 55,901 |
|
| 85,062 |
|
|
| 80,457 |
|
Commitments and contingencies (Note 11) |
|
|
|
|
| |||||||||
Commitments and contingencies (Note 12) |
|
|
|
|
| |||||||||
STOCKHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
|
| ||||
Preferred stock, par value $.000001, 25,000 shares authorized, NaN issued |
| — |
|
|
| — |
|
| — |
|
|
| — |
|
Common stock, par value $.000001, 120,000 shares authorized, 72,038 and 71,738 shares |
| 0 |
|
|
| 0 |
| |||||||
Common stock, par value $.000001, 120,000 shares authorized, 72,572 and 72,069 shares issued and outstanding |
| 0 |
|
|
| 0 |
| |||||||
Additional paid-in capital |
| 508,601 |
|
|
| 505,123 |
|
| 515,928 |
|
|
| 511,063 |
|
Accumulated other comprehensive loss |
| (10,721 | ) |
|
| (9,097 | ) |
| (12,514 | ) |
|
| (10,077 | ) |
Accumulated deficit |
| (110,060 | ) |
|
| (97,455 | ) |
| (159,222 | ) |
|
| (120,453 | ) |
Total stockholders' equity |
| 387,820 |
|
|
| 398,571 |
|
| 344,192 |
|
|
| 380,533 |
|
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 455,757 |
|
| $ | 454,472 |
| $ | 429,254 |
|
| $ | 460,990 |
|
See accompanying notes to the consolidated financial statements.
3
ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(in thousands, except per share amounts)
|
| Three Months Ended September 30, |
|
| Nine Months Ended September 30, |
|
| Three Months Ended June 30, |
|
| Six Months Ended June 30, |
| ||||||||||||||||||||
|
| 2021 |
| 2020 |
|
| 2021 |
|
| 2020 |
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| |||||||||
NET REVENUES: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||
Products and services |
| $ | 53,229 |
|
| $ | 46,749 |
|
| $ | 165,549 |
|
| $ | 105,972 |
|
| $ | 79,167 |
|
| $ | 55,741 |
|
| $ | 144,403 |
|
| $ | 112,320 |
|
Other |
|
| 688 |
|
|
| 1,262 |
|
|
| 4,557 |
|
|
| 2,894 |
|
|
| 1,064 |
|
|
| 1,866 |
|
|
| 3,535 |
|
|
| 3,869 |
|
|
|
| 53,917 |
|
|
| 48,011 |
|
|
| 170,106 |
|
|
| 108,866 |
|
|
| 80,231 |
|
|
| 57,607 |
|
|
| 147,938 |
|
|
| 116,189 |
|
COST OF PRODUCTS AND SERVICES SOLD |
|
| 32,449 |
|
|
| 17,722 |
|
|
| 79,639 |
|
|
| 45,182 |
|
|
| 52,647 |
|
|
| 26,934 |
|
|
| 96,082 |
|
|
| 47,190 |
|
Gross profit |
|
| 21,468 |
|
|
| 30,289 |
|
|
| 90,467 |
|
|
| 63,684 |
|
|
| 27,584 |
|
|
| 30,673 |
|
|
| 51,856 |
|
|
| 68,999 |
|
OPERATING EXPENSES: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||
Research and development |
|
| 8,596 |
|
|
| 8,007 |
|
|
| 25,270 |
|
|
| 20,575 |
|
|
| 9,068 |
|
|
| 7,682 |
|
|
| 17,481 |
|
|
| 16,674 |
|
Sales and marketing |
|
| 13,886 |
|
|
| 7,849 |
|
|
| 33,836 |
|
|
| 25,339 |
|
|
| 11,684 |
|
|
| 10,420 |
|
|
| 24,401 |
|
|
| 19,950 |
|
General and administrative |
|
| 12,499 |
|
|
| 10,108 |
|
|
| 33,680 |
|
|
| 30,442 |
|
|
| 17,579 |
|
|
| 10,993 |
|
|
| 36,735 |
|
|
| 21,181 |
|
Loss on impairment |
|
| 10,542 |
|
|
| — |
|
|
| 10,542 |
|
|
| — |
| ||||||||||||||||
Change in the estimated fair value of acquisition-related contingent consideration |
|
| (500 | ) |
|
| (60 | ) |
|
| (1,526 | ) |
|
| 390 |
|
|
| — |
|
|
| (220 | ) |
|
| (36 | ) |
|
| (1,026 | ) |
|
|
| 34,481 |
|
|
| 25,904 |
|
|
| 91,260 |
|
|
| 76,746 |
|
|
| 48,873 |
|
|
| 28,875 |
|
|
| 89,123 |
|
|
| 56,779 |
|
Operating income (loss) |
|
| (13,013 | ) |
|
| 4,385 |
|
|
| (793 | ) |
|
| (13,062 | ) |
|
| (21,289 | ) |
|
| 1,798 |
|
|
| (37,267 | ) |
|
| 12,220 |
|
OTHER INCOME |
|
| 100 |
|
|
| 314 |
|
|
| 429 |
|
|
| 1,960 |
|
|
| 1,318 |
|
|
| 448 |
|
|
| 1,265 |
|
|
| 329 |
|
Income (loss) before income taxes |
|
| (12,913 | ) |
|
| 4,699 |
|
|
| (364 | ) |
|
| (11,102 | ) |
|
| (19,971 | ) |
|
| 2,246 |
|
|
| (36,002 | ) |
|
| 12,549 |
|
INCOME TAX EXPENSE |
|
| 2,102 |
|
|
| 3,659 |
|
|
| 12,241 |
|
|
| 5,680 |
| ||||||||||||||||
INCOME TAX EXPENSE (BENEFIT) |
|
| (1,169 | ) |
|
| 3,610 |
|
|
| 2,767 |
|
|
| 10,139 |
| ||||||||||||||||
NET INCOME (LOSS) |
| $ | (15,015 | ) |
| $ | 1,040 |
|
| $ | (12,605 | ) |
| $ | (16,782 | ) |
| $ | (18,802 | ) |
| $ | (1,364 | ) |
| $ | (38,769 | ) |
| $ | 2,410 |
|
INCOME (LOSS) PER SHARE: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||||
BASIC |
| $ | (0.21 | ) |
| $ | 0.01 |
|
| $ | (0.18 | ) |
| $ | (0.25 | ) |
| $ | (0.26 | ) |
| $ | (0.02 | ) |
| $ | (0.54 | ) |
| $ | 0.03 |
|
DILUTED |
| $ | (0.21 | ) |
| $ | 0.01 |
|
| $ | (0.18 | ) |
| $ | (0.25 | ) |
| $ | (0.26 | ) |
| $ | (0.02 | ) |
| $ | (0.54 | ) |
| $ | 0.03 |
|
SHARES USED IN COMPUTING INCOME (LOSS) PER SHARE: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||
BASIC |
|
| 72,023 |
|
|
| 71,537 |
|
|
| 71,962 |
|
|
| 66,088 |
|
|
| 72,496 |
|
|
| 71,983 |
|
|
| 72,361 |
|
|
| 71,931 |
|
DILUTED |
|
| 72,023 |
|
|
| 72,662 |
|
|
| 71,962 |
|
|
| 66,088 |
|
|
| 72,496 |
|
|
| 71,983 |
|
|
| 72,361 |
|
|
| 72,683 |
|
See accompanying notes to the consolidated financial statements.
4
ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(Unaudited)
(in thousands)
|
| Three Months Ended September 30, |
|
| Nine Months Ended September 30, |
|
| Three Months Ended June 30, |
|
| Six Months Ended June 30, |
| ||||||||||||||||||||
|
| 2021 |
| 2020 |
|
| 2021 |
| 2020 |
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||||||||
NET INCOME (LOSS) |
| $ | (15,015 | ) |
| $ | 1,040 |
|
| $ | (12,605 | ) |
| $ | (16,782 | ) |
| $ | (18,802 | ) |
| $ | (1,364 | ) |
| $ | (38,769 | ) |
| $ | 2,410 |
|
OTHER COMPREHENSIVE INCOME (LOSS) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||||
Currency translation adjustments |
|
| (4,117 | ) |
|
| 1,953 |
|
|
| (1,362 | ) |
|
| (3,542 | ) |
|
| (4,349 | ) |
|
| 1,403 |
|
|
| (2,593 | ) |
|
| 2,755 |
|
Unrealized gain (loss) on marketable securities |
|
| (161 | ) |
|
| (266 | ) |
|
| (262 | ) |
|
| 83 |
|
|
| 82 |
|
|
| (122 | ) |
|
| 156 |
|
|
| (101 | ) |
COMPREHENSIVE INCOME (LOSS) |
| $ | (19,293 | ) |
| $ | 2,727 |
|
| $ | (14,229 | ) |
| $ | (20,241 | ) |
| $ | (23,069 | ) |
| $ | (83 | ) |
| $ | (41,206 | ) |
| $ | 5,064 |
|
See accompanying notes to the consolidated financial statements.
5
ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(in thousands)
|
| Nine Months Ended September 30, |
|
| Six Months Ended June 30, |
| ||||||||||
|
| 2021 |
|
| 2020 |
|
| 2022 |
|
| 2021 |
| ||||
OPERATING ACTIVITIES: |
|
|
|
|
|
|
|
|
|
| ||||||
Net loss |
| $ | (12,605 | ) |
| $ | (16,782 | ) | ||||||||
Adjustments to reconcile net loss to net cash (used in) provided by operating activities: |
|
|
|
|
| |||||||||||
Net income (loss) |
| $ | (38,769 | ) |
| $ | 2,410 |
| ||||||||
Adjustments to reconcile net income (loss) to net cash used in operating activities: |
|
|
|
|
| |||||||||||
Stock-based compensation |
|
| 5,155 |
|
|
| 5,913 |
|
|
| 6,804 |
|
|
| 2,937 |
|
Depreciation and amortization |
|
| 8,479 |
|
|
| 6,880 |
|
|
| 7,464 |
|
|
| 5,144 |
|
Loss on impairment |
|
| 10,542 |
|
|
| — |
| ||||||||
Other non-cash amortization |
|
| 664 |
|
|
| 171 |
|
|
| 313 |
|
|
| 380 |
|
Provision for doubtful accounts |
|
| 1,228 |
|
|
| 1,141 |
|
|
| (152 | ) |
|
| 747 |
|
Inventory reserve |
|
| 1,989 |
|
|
| 1,168 |
| ||||||||
Unrealized foreign currency gain |
|
| (319 | ) |
|
| (41 | ) |
|
| (62 | ) |
|
| (364 | ) |
Interest expense on finance leases |
|
| 84 |
|
|
| 56 |
|
|
| 55 |
|
|
| 35 |
|
Deferred income taxes |
|
| (324 | ) |
|
| (764 | ) |
|
| 361 |
|
|
| (218 | ) |
Loss on sale of fixed assets |
|
| — |
|
|
| 104 |
| ||||||||
Loss on disposal of fixed assets |
|
| 718 |
|
|
| — |
| ||||||||
Change in the estimated fair value of acquisition-related contingent consideration |
|
| (1,526 | ) |
|
| 390 |
|
|
| (36 | ) |
|
| (1,026 | ) |
Payment of acquisition-related contingent consideration |
|
| (142 | ) |
|
| (496 | ) |
|
| — |
|
|
| (142 | ) |
Changes in assets and liabilities |
|
|
|
|
|
|
|
|
|
| ||||||
Accounts receivable |
|
| (2,102 | ) |
|
| 5,228 |
|
|
| (18,646 | ) |
|
| 3,680 |
|
Inventories |
|
| (21,689 | ) |
|
| (7,425 | ) |
|
| (20,385 | ) |
|
| (17,233 | ) |
Prepaid expenses and other assets |
|
| (1,942 | ) |
|
| 2,420 |
|
|
| (4,416 | ) |
|
| 154 |
|
Accounts payable |
|
| 2,790 |
|
|
| 3,269 |
|
|
| 11,942 |
|
|
| 4,400 |
|
Deferred revenue |
|
| (1,331 | ) |
|
| 1,664 |
|
|
| (252 | ) |
|
| (630 | ) |
Accrued expenses and other liabilities |
|
| 982 |
|
|
| 468 |
|
|
| (2,959 | ) |
|
| (4,914 | ) |
Net cash (used in) provided by operating activities |
|
| (22,598 | ) |
|
| 2,196 |
| ||||||||
Net cash used in operating activities |
|
| (45,489 | ) |
|
| (3,472 | ) | ||||||||
INVESTING ACTIVITIES: |
|
|
|
|
|
|
|
|
|
| ||||||
Purchases of investments |
|
| (25,443 | ) |
|
| (90,137 | ) |
|
| — |
|
|
| (10,428 | ) |
Proceeds from maturities and redemptions of investments |
|
| 53,745 |
|
|
| 102,616 |
|
|
| 23,017 |
|
|
| 43,745 |
|
Purchases of property and equipment |
|
| (27,508 | ) |
|
| (11,234 | ) |
|
| (25,440 | ) |
|
| (22,929 | ) |
Proceeds from escrow associated with business acquisitions |
|
| — |
|
|
| 126 |
| ||||||||
Acquisition of businesses, net of cash acquired |
|
| — |
|
|
| (3,037 | ) | ||||||||
Purchase price adjustment related to business acquisition |
|
| (18 | ) |
|
| — |
| ||||||||
Purchase of patent and product rights |
|
| — |
|
|
| (2,250 | ) | ||||||||
Purchase of property and equipment under government contracts |
|
| (33,803 | ) |
|
| — |
| ||||||||
Proceeds from funding under government contract |
|
| 33,962 |
|
|
| — |
| ||||||||
Other investing activities |
|
| — |
|
|
| (18 | ) | ||||||||
Net cash (used in) provided by investing activities |
|
| 776 |
|
|
| (3,916 | ) |
|
| (2,264 | ) |
|
| 10,370 |
|
FINANCING ACTIVITIES: |
|
|
|
|
|
|
|
|
|
| ||||||
Cash payments for lease liabilities |
|
| (1,111 | ) |
|
| (521 | ) |
|
| (392 | ) |
|
| (510 | ) |
Proceeds from exercise of stock options |
|
| 15 |
|
|
| 121 |
| ||||||||
Payment of acquisition-related contingent consideration |
|
| (264 | ) |
|
| (3,004 | ) |
|
| (208 | ) |
|
| (264 | ) |
Issuance of common stock in connection with public offering, net |
|
| — |
|
|
| 95,036 |
| ||||||||
Proceeds from exercise of stock options |
|
| 247 |
|
|
| 2,115 |
| ||||||||
Repurchase of common stock |
|
| (1,924 | ) |
|
| (2,076 | ) |
|
| (1,954 | ) |
|
| (1,877 | ) |
Net cash (used in) provided by financing activities |
|
| (3,052 | ) |
|
| 91,550 |
| ||||||||
Net cash used in financing activities |
|
| (2,539 | ) |
|
| (2,530 | ) | ||||||||
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH |
|
| (966 | ) |
|
| (2,686 | ) |
|
| (311 | ) |
|
| (7,050 | ) |
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS |
|
| (25,840 | ) |
|
| 87,144 |
| ||||||||
NET DECREASE IN CASH AND CASH EQUIVALENTS |
|
| (50,603 | ) |
|
| (2,682 | ) | ||||||||
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD |
|
| 160,802 |
|
|
| 75,715 |
|
|
| 116,762 |
|
|
| 160,802 |
|
CASH AND CASH EQUIVALENTS, END OF PERIOD |
| $ | 134,962 |
|
| $ | 162,859 |
|
| $ | 66,159 |
|
| $ | 158,120 |
|
|
|
|
|
|
| |||||||||||
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Cash paid for income taxes |
| $ | 12,540 |
|
| $ | 3,888 |
|
| $ | 9,107 |
|
| $ | 10,329 |
|
Non-cash investing and financing activities |
|
|
|
|
|
|
|
|
|
| ||||||
Accrued property and equipment purchases |
| $ | 4,382 |
|
| $ | 2,093 |
|
|
| 1,900 |
|
|
| 896 |
|
Accrued property and equipment purchases under government contracts |
|
| 2,023 |
|
|
| — |
| ||||||||
Unrealized gain (loss) on marketable securities |
| $ | (262 | ) |
| $ | 83 |
|
|
| 156 |
|
|
| (101 | ) |
See accompanying notes to the consolidated financial statements.
6
ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(in thousands, except per share amounts, unless otherwise indicated)
1.The Company
The overall goal of OraSure Technologies, Inc. (“OraSure” or “the Company”) is to empower the global community to improve health and wellness by providing access to accurate essential information. Our business consists of 2 segments: our “Diagnostics” segment, and our “Molecular Solutions” segment.
Our Diagnostics business primarily consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using our proprietary technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Diagnostics business includes tests for diseases including HIV and Hepatitis C that are performed on a rapid basis at the point of care and tests that are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Our HIV product is also sold in a consumer-friendly format in the over-the-counter (“OTC”) market in the U.S. and as a self-test to individuals in a number of other countries. Our Diagnostics business includes the operations of UrSure, Inc. (“UrSure”), which was acquired and merged into OraSure in 2020. This part of the Diagnostics business develops and commercializes products that measure adherence to HIV medications including pre-exposure prophylaxis or PrEP, the daily medication to prevent HIV, and anti-retroviral medications to suppress HIV. These products include laboratory-based tests that can measure levels of the medications in a patient’s urine or blood, as well as point-of-care products currently in development. In 2020, we began developing a rapid antigen self-test for COVID-19 and a COVID-19 antibody enzyme-linked immunosorbent assay (“ELISA”) for use in laboratory settings. In June 2021, we received three Emergency Use Authorizations ("EUA") from the U.S. Food and Drug Administration ("FDA") for our InteliSwabTM COVID-19 Rapid Antigen Tests for non-prescription OTC, professional point-of-care and prescription use. We began recording revenues on the sales of our InteliSwabTM COVID-19 Rapid Antigen Tests during the third quarter of 2021. Following discussions with the FDA and their de-prioritization of antibody testing in the U.S., we decided to no longer pursue EUAs for the ELISA test. We have, however, continued to offer the product for research use to labs and other parties interested in COVID antibody surveillance and research applications.
Our Molecular Solutions business is operated by our subsidiaries, DNA Genotek Inc. (“DNAG”), Diversigen, Inc. (“Diversigen”), and Novosanis NV (“Novosanis”). In our DNAG business, we manufacture and sell kits that are used to collect, stabilize, transport and store a biological sample of genetic material for molecular testing. Our products are used for academic research and commercial applications, including ancestry, disease risk management, lifestyle and animal testing. Three of our collection devices are used in connection with COVID-19 molecular testing. We also sell research-use-only collection products into the microbiome market. We offer our customers a suite of genomics and microbiome services that range from package customization and study design optimization to extraction, analysis and reporting services. The microbiome laboratory and bioinformatics services are provided by Diversigen, which includes the operations of CoreBiome, Inc. (“CoreBiome”), a subsidiary we acquired in early 2019. CoreBiome and Diversigen were merged together in 2020. Novosanis manufactures and sells the Colli-Pee® collection device for the volumetric collection of first-void urine for use in research, screening and diagnostics in the liquid biopsy and sexually transmitted infection markets. Our Molecular Solutions business serves customers in many countries worldwide, including many leading research universities and hospitals.
2.1. Summary of Significant Accounting Policies
Principles of Consolidation and Basis of Presentation. The accompanying interim unaudited consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiaries, DNAG,DNA Genotek Inc. (“DNAG”), Diversigen, Inc. (“Diversigen”), and Novosanis.Novosanis NV (“Novosanis”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated. The unaudited financial statements, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.2021. Results of operations for the three and ninesix months ended SeptemberJune 30, 20212022 are not necessarily indicative of the results of operations expected for the full year.
Summary of Significant Accounting Policies. There have been no changes to the Company's significant accounting policies described in our Annual Report on Form 10-K for the fiscal year ended December 31, 20202021 that have had a material impact on the consolidated financial statements and related notes except as discussed herein.
7
Investments. We consider all investments in debt securities to be available-for-sale securities. These securities consist of guaranteed investment certificates and corporate bonds purchased with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.
We record an allowance for credit loss for our available-for-sale securities when a decline in investment market value is due to credit-related factors. When evaluating an investment for impairment, we review factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, the Company’s intent to sell or the likelihood that it would be required to sell the investment before its anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. As of SeptemberDuring the six months ended June 30, 2021,2022, we determined that the decline in the market value ofrecognized a provision for expected credit losses for our available-for-sale investment was not due to credit-related factors and as such no allowance for credit-loss was necessary.securities of $72.
The following is a summary of our available-for-sale securities as of SeptemberJune 30, 20212022 and December 31, 2020:2021:
|
| Amortized |
| Gross |
| Gross |
| Fair Value |
|
| Amortized |
|
| Gross |
|
| Gross |
|
| Fair Value |
| |||||||||||
September 30, 2021 |
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||
June 30, 2022 |
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||
Guaranteed investment certificates |
| $ | 33,122 |
|
| $ | 0 |
|
| $ | 0 |
|
| $ | 33,122 |
|
| $ | 24,860 |
|
| $ | — |
|
| $ | — |
|
| $ | 24,860 |
|
Corporate bonds |
|
| 34,824 |
|
|
| 0 |
|
|
| (610 | ) |
|
| 34,214 |
|
|
| 5,043 |
|
|
| — |
|
|
| (278 | ) |
|
| 4,765 |
|
Total available-for-sale securities |
| $ | 67,946 |
|
| $ | 0 |
|
| $ | (610 | ) |
| $ | 67,336 |
|
| $ | 29,903 |
|
| $ | — |
|
| $ | (278 | ) |
| $ | 29,625 |
|
December 31, 2020 |
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||
December 31, 2021 |
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||
Guaranteed investment certificates |
| $ | 25,132 |
|
| $ | 0 |
|
| $ | 0 |
|
| $ | 25,132 |
|
| $ | 33,249 |
|
| $ | — |
|
| $ | — |
|
| $ | 33,249 |
|
Corporate bonds |
|
| 71,533 |
|
|
| 135 |
|
|
| (483 | ) |
|
| 71,185 |
|
|
| 20,473 |
|
|
| — |
|
|
| (434 | ) |
|
| 20,039 |
|
Total available-for-sale securities |
| $ | 96,665 |
|
| $ | 135 |
|
| $ | (483 | ) |
| $ | 96,317 |
|
| $ | 53,722 |
|
| $ | — |
|
| $ | (434 | ) |
| $ | 53,288 |
|
At September 30, 2021, maturities of our available-for-sale |
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||
At June 30, 2022, maturities of our available-for-sale |
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||
Less than one year |
| $ | 50,510 |
|
| $ | 0 |
|
| $ | (445 | ) |
| $ | 50,065 |
|
| $ | 29,903 |
|
| $ | — |
|
| $ | (278 | ) |
| $ | 29,625 |
|
Greater than one year |
| $ | 17,436 |
|
| $ | 0 |
|
| $ | (165 | ) |
| $ | 17,271 |
|
| $ | — |
|
| $ | — |
|
| $ | — |
|
| $ | — |
|
Fair Value of Financial Instruments. As of SeptemberJune 30, 20212022 and December 31, 2020,2021, the carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their respective fair values based on their short-term nature.
Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:
Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
7
Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and
Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
All of our available-for-sale debt securities are measured as Level 2 instruments as of SeptemberJune 30, 20212022 and December 31, 2020.2021. Our available-for-sale guaranteed investment certificates are measured as Level 1 instruments as of SeptemberJune 30, 20212022 and December 31, 2020.2021.
Included in cash and cash equivalents at SeptemberJune 30, 20212022 and December 31, 2020,2021, was $23,8625,636 and $71,4891,160 invested in government money market funds. These funds have investments in government securities and are measured as Level 1 instruments.
We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and company stock. The fair value of the plan assets as of SeptemberJune 30, 20212022 and December 31, 20202021 was $2,5031,576 and $2,5651,763, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in both current assets and noncurrent assets with the same amount included in accrued expenses and other noncurrent liabilities in the accompanying consolidated balance sheets.
8
Accounts Receivable. Accounts receivable have been reduced by an estimated allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as they become past due, the financial condition of our customers and our historical experience related to write-offs.
Inventories. Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis, and include the cost of raw materials, labor and overhead. The majority of our inventories are subject to expiration dating, which can be extended in certain circumstances. We continually evaluate quantities on hand and the carrying value of our inventories to determine the need for reserves for excess and obsolete inventories, based on prior experience as well as estimated forecasts of product sales. We reserve for unidentified scrap or spoilage based on historical write-off rates. We also consider items identified through specific identification procedures in assessing the adequacy of our reserve. When factors indicate that impairment has occurred, either a reserve is established against the inventories’ carrying value or the inventories are completely written off, as in the case of lapsing expiration dates. During the third quarter of 2021, we reserved $1,750 of COVID-19 antibody inventory, which we do not believe we can sell as a result of the decision to no longer pursue EUAs for the ELISA test.
Property, Plant and Equipment. Property, plant and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations. Accumulated depreciation of property, plant and equipment as of SeptemberJune 30, 20212022 and December 31, 20202021 was $58,75566,468 and $53,60461,157, respectively.
Intangible Assets. Intangible assets consist of customer relationships, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses, and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of five to fifteen years. Accumulated amortization of intangible assets as of SeptemberJune 30, 20212022 and December 31, 20202021 was $29,55430,988 and $27,10730,412, respectively. The decrease in intangiblesintangible assets from $17,90414,343 as of December 31, 20202021 to $15,22112,851 as of SeptemberJune 30, 20212022 was due to $2,4551,120 in amortization expense and foreign currency translation losses of $228372.
GoodwillImpairment of Long-Lived Assets. Goodwill representsLong-lived assets, which include property and equipment and definite-lived intangible assets, are tested for recoverability whenever events or changes in business circumstances indicate that the excesscarrying amount of the purchase priceassets may not be fully recoverable. We assess the recoverability of our long-lived assets by determining whether the carrying value of such assets can be recovered through the sum of the undiscounted future cash flows generated from the use and eventual disposition of the asset. If indicators of impairment exist, we measure the amount of such impairment by comparing the carrying value of the assets to the fair value of these assets, which is generally determined based on the present value of the expected future cash flows associated with the use of the assets. Expected future cash flows reflect our assumptions about selling prices, volumes, costs and market conditions over a reasonable period of time.
During the three months ended June 30, 2022, management decided to move three idle manufacturing cells to storage due to changes in forecasted demand for the products the cells are intended to produce. As a result of this decision, we determined that the carrying values of the equipment is not recoverable and recorded an aggregate pre-tax asset impairment charge of $6,938 during the three months ended June 30, 2022 to write the assets down their estimated fair values. This charge is reported within loss on impairments in the consolidated statement of operations.
We estimated the fair value of the net tangible and identifiable intangibleimpaired long-lived assets acquired. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current generally accepted accounting principles (“GAAP”) permitusing a market approach, which required us to make a qualitative evaluation aboutestimate the likelihoodvalue that would be received for the equipment in the principal or most advantageous market for that equipment in an orderly transaction between market participants. Due to the extremely specialized nature of goodwill impairment. If we conclude that it is more likely than not that the carrying value of a reporting unit is greater than itsmanufacturing equipment and various market data points, the estimated fair value then we would be required to recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’swas not significant. Our fair value providedestimates were representative of Level 3 measurements within the impairment charge does not exceed the total amount of goodwill allocatedfair value hierarchy due to the reporting unit.significant level of estimation involved and the lack of transparency as to the inputs used.
The decrease in goodwill from $40,351 as of December 31, 2020 to $40,264 as of September 30, 2021 was a result of an adjustment of $105 associated with foreign currency translation and a purchase price adjustment of $18 related to a business acquisition.
Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.
Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than a functional currency are included in our consolidated statements of incomeoperations in the period in which the change occurs. Net foreign exchange gains resulting from
8
foreign currency transactions that are included in other income (loss) in our consolidated statements of incomeoperations were $7783 and $70198 for the three months ended SeptemberJune 30, 20212022 and 2020,2021, respectively. Net foreign exchange gains (losses) were $54 and $(371379) and $563for the ninesix months ended SeptemberJune 30, 2022 and 2021, and 2020.respectively.
Accumulated Other Comprehensive Income (Loss)Loss. We classify items of other comprehensive income (loss)loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our consolidated balance sheets.
We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and we have defined the Euro as the functional currency of our Belgian subsidiary, Novosanis. The results of operations for those subsidiaries are translated into U.S. dollars, which is the reporting currency of the Company. Accumulated other comprehensive loss at SeptemberJune 30, 20212022 consisted of $10,11112,236 of currency translation adjustments and $610278 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our
9
investment portfolio. Accumulated other comprehensive loss at December 31, 20202021 consists of $8,7499,643 of currency translation adjustments and $348434 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our investments portfolio.
Recent Accounting Pronouncements.
In March 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-04, Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The purpose of this update is to provide optional guidance for a limited time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in this update are elective and areASU were effective upon issuance and could be applied prospectively through December 31, 2022. The FASB issued a proposed amendment to the ASU in April 2022 which, if approved, will extend the date for all entities.prospective application to December 31, 2024. Management is evaluating the impact ofhas evaluated this ASU and doesconcluded that it will not expect this update to have a material impact on the Company's Consolidated Financial Statements.
2. Government Capital Contracts
3. Business CombinationsIn September 2021, we entered into an agreement for $109,000 in funding from the U.S. Department of Defense (the “DOD”), in coordination with the Department of Health and Human Services, to build additional manufacturing capacity in the United States for our InteliSwab® COVID-19 Rapid Tests as part of the nation’s pandemic preparedness plan. Funding will be paid to the Company based on achievement of milestones through March 2024 for the design, acquisition, installation, qualification and acceptance of the manufacturing equipment, as set forth in the agreement. In accordance with the milestone payment schedule, 15% of the total will not be funded until the completion of the final equipment validation, which is scheduled to occur in late 2023 or early 2024. We began making payments to vendors for the capital project during the fourth quarter of 2021 and began receiving funds from the DOD in January 2022.
UrSure
On July 22, 2020, the Company acquired all of the outstanding capital stock of UrSure, Inc. (“UrSure”), pursuant to the terms of a merger agreement. The initial aggregate purchase price of this transaction wasAdditionally, during 2021, we received $3,000531, adjusted in funding from the Commonwealth of Pennsylvania, acting through the Department of Community and Economic Development, for certain transaction costs, indebtedness, and holdback amounts, and was funded with cash on hand. A portion of the purchase price was deposited intoof machinery and equipment as part of an escrow account for a limited period after closing, pursuant to indemnification obligations under the merger agreement.
During the nine months ended September 30, 2020, we incurred acquisitionexpansion of manufacturing operations in Pennsylvania. All related costs of $393 including accounting, legal, and other professional fees, all of whichpurchases were expensed and reported as a component of general and administrative expensecompleted in the consolidated statement of operations. NaN such costs were incurred for the nine months ended September 30, 2021.
PursuantActivity for these capital contracts is accounted for pursuant to International Accounting Standard ("IAS") 20, Accounting for Government Grants and Disclosure of Government Assistance. Funding earned in relation to capital-related costs incurred for government contracts is recorded as a reduction to the cost of property, plant and equipment and reflected within investing activities in the consolidated statements of cash flows; and associated unpaid liabilities and government proceeds receivable are considered non-cash changes in such balances within the operating section of the consolidated statements of cash flows. Amounts earned in excess of our merger agreement, we were to pay up to an additionalexpected cost of the project for project management are recognized straight-line in other income over the term of the government contract. We recognized $28,000561 and $1,123 of contingent consideration oversuch income for the three years following the acquisition date based on the achievementand six months ended June 30, 2022, respectively, which is reported as other income (loss) in our consolidated statement of certain performance criteria as defined under the agreements, including generating certain revenue dollars, and the achievement of certain clinical milestones associated with the development of certain new technology. The Company, with the assistance of an independent valuation specialist, determines the estimated fair value of the contingent consideration. The fair value is determined using a probability-weighted model based on our assessment of the likelihood that the benchmarks will be achieved. The probability-weighted payments were then discounted using a discount rate based on an internal rate of return analysis using the probability-weighted cash flows. The fair value measurement is based on significant inputs, including the likelihood of the achievement of clinical milestones and revenue forecasts, not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy.operations.
The following table represents the change in contingent consideration:
Balance as of December 31, 2020 | $ | 2,451 | �� |
Payments made during the period |
| (406 | ) |
Change in fair value during the period |
| (1,526 | ) |
Balance as of September 30, 2021 | $ | 519 |
|
The change in fair value during the nine months ended September 30, 2021 is as a result of delays in achieving certain product development milestones and a decrease in associated revenue forecasts as a result of these delays.
Revenues from UrSure primarily consist of grant money receivedbalances corresponding to fund the development of certain new technology. Effective as of July 22, 2020, the financial results of UrSure aregovernment contracts included in our Diagnostics segment.consolidated balance sheet are as follows:
9
| June 30, 2022 |
|
| December 31, 2021 |
| ||
Other current assets: |
|
|
|
|
| ||
Billed receivables | $ | — |
|
| $ | 9,913 |
|
Unbilled receivables |
| 15,748 |
|
|
| 9,716 |
|
Total other current assets |
| 15,748 |
|
|
| 19,629 |
|
Property, plant and equipment, net: |
|
|
|
|
| ||
Cost of assets, cumulative |
| 47,321 |
|
|
| 11,495 |
|
Reduction for funding earned to date, not yet received |
| (12,828 | ) |
|
| (10,964 | ) |
Reduction for funding received to date |
| (34,493 | ) |
|
| (531 | ) |
Total property, plant and equipment, net |
| — |
|
|
| 0 |
|
Accrued expenses and other current liabilities |
| (620 | ) |
|
| (8,103 | ) |
3. Inventories
4. Inventories
|
| June 30, 2022 |
|
| December 31, 2021 |
| ||
Raw materials |
| $ | 37,292 |
|
| $ | 33,168 |
|
Work in process |
|
| 2,348 |
|
|
| 2,252 |
|
Finished goods |
|
| 31,664 |
|
|
| 17,718 |
|
|
| $ | 71,304 |
|
| $ | 53,138 |
|
|
| September 30, |
|
| December 31, |
| ||
Raw materials |
| $ | 28,306 |
|
| $ | 15,425 |
|
Work in process |
|
| 2,653 |
|
|
| 2,572 |
|
Finished goods |
|
| 22,624 |
|
|
| 13,866 |
|
|
| $ | 53,583 |
|
| $ | 31,863 |
|
10
5.4. Earnings (Loss) Per Share
Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed in a manner similar to basic earnings (loss) per share except that the weighted-average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock or performance stock units, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period. Basic and dilutive computations of net loss per share are the same in periods in which a net loss exists as the dilutive effects of excluded items would be anti-dilutive.
The computations of basic and diluted earnings (loss) per share are as follows:
|
| Three Months |
| Nine Months |
| |||||||||||||||||||||||||||
|
| Ended September 30, |
| Ended September 30, |
|
| Three Months Ended June 30, |
| Six Months Ended June 30, |
| ||||||||||||||||||||||
|
| 2021 |
| 2020 |
| 2021 |
| 2020 |
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| |||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||||
Net income (loss) |
| $ | (15,015 | ) |
| $ | 1,040 |
|
| $ | (12,605 | ) |
| $ | (16,782 | ) |
| $ | (18,802 | ) |
| $ | (1,364 | ) |
| $ | (38,769 | ) |
| $ | 2,410 |
|
Weighted-average shares of common stock outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||||
Basic |
|
| 72,023 |
|
|
| 71,537 |
|
|
| 71,962 |
|
|
| 66,088 |
|
|
| 72,496 |
|
|
| 71,983 |
|
|
| 72,361 |
|
|
| 71,931 |
|
Dilutive effect of stock options, restricted stock, and performance stock units |
|
| — |
|
|
| 1,125 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 752 |
|
Diluted |
|
| 72,023 |
|
|
| 72,662 |
|
|
| 71,962 |
|
|
| 66,088 |
|
|
| 72,496 |
|
|
| 71,983 |
|
|
| 72,361 |
|
|
| 72,683 |
|
Earnings (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||||
Basic |
| $ | (0.21 | ) |
| $ | 0.01 |
|
| $ | (0.18 | ) |
| $ | (0.25 | ) |
| $ | (0.26 | ) |
| $ | (0.02 | ) |
| $ | (0.54 | ) |
| $ | 0.03 |
|
Diluted |
| $ | (0.21 | ) |
| $ | 0.01 |
|
| $ | (0.18 | ) |
| $ | (0.25 | ) |
| $ | (0.26 | ) |
| $ | (0.02 | ) |
| $ | (0.54 | ) |
| $ | 0.03 |
|
For the three months ended SeptemberJune 30, 2022, three months ended June 30, 2021 and six months ended June 30, 2022, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 226, 603, and 381 shares, respectively, were excluded from the computation of diluted loss per share. For the six months ended June 30, 2021, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 859 shares were excluded from the computation of diluted loss per share. For the three months ended September 30, 2020, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 136604 shares were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive.For the nine months ended September 30, 2021 and 2020, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 847 and 917 shares, respectively, were excluded from the computation of diluted loss per share.
10
6.5. Revenues
Revenues by product line. The following table represents total net revenues by product line:
|
| Three Months Ended June 30, | Six Months Ended June 30, |
| ||||||||||||
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||
COVID-19 (1) |
| $ | 43,378 |
|
| $ | 12,070 |
|
| $ | 74,411 |
|
| $ | 40,215 |
|
Genomics (1) |
|
| 15,486 |
|
|
| 19,498 |
|
|
| 30,578 |
|
|
| 30,316 |
|
HIV |
|
| 10,357 |
|
|
| 10,944 |
|
|
| 18,523 |
|
|
| 19,722 |
|
HCV |
|
| 3,691 |
|
|
| 4,300 |
|
|
| 6,948 |
|
|
| 6,668 |
|
Substance abuse |
|
| 2,630 |
|
|
| 2,629 |
|
|
| 5,191 |
|
|
| 4,591 |
|
Microbiome (1) |
|
| 1,832 |
|
|
| 2,447 |
|
|
| 3,822 |
|
|
| 4,198 |
|
Laboratory services |
|
| 1,204 |
|
|
| 3,114 |
|
|
| 2,938 |
|
|
| 5,611 |
|
Other product and service revenues |
|
| 589 |
|
|
| 739 |
|
|
| 1,992 |
|
|
| 999 |
|
Net product and services revenues |
|
| 79,167 |
|
|
| 55,741 |
|
|
| 144,403 |
|
|
| 112,320 |
|
Royalty income |
|
| 642 |
|
|
| 875 |
|
|
| 1,326 |
|
|
| 2,136 |
|
Other non-product revenues |
|
| 422 |
|
|
| 991 |
|
|
| 2,209 |
|
|
| 1,733 |
|
Other revenues |
|
| 1,064 |
|
|
| 1,866 |
|
|
| 3,535 |
|
|
| 3,869 |
|
Net revenues |
| $ | 80,231 |
|
| $ | 57,607 |
|
| $ | 147,938 |
|
| $ | 116,189 |
|
|
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
|
| 2021 |
|
| 2020 |
|
| 2021 |
|
| 2020 |
|
| ||||
Infectious disease testing |
| $ | 12,932 |
|
| $ | 13,224 |
|
| $ | 39,664 |
|
| $ | 36,625 |
|
|
Risk assessment testing |
|
| 2,674 |
|
|
| 2,253 |
|
|
| 7,265 |
|
|
| 6,786 |
|
|
Genomics (1) |
|
| 19,018 |
|
|
| 8,454 |
|
|
| 49,333 |
|
|
| 23,224 |
|
|
Microbiome (1) |
|
| 1,693 |
|
|
| 1,530 |
|
|
| 5,888 |
|
|
| 3,869 |
|
|
COVID-19 (1) |
|
| 13,930 |
|
|
| 18,867 |
|
|
| 54,147 |
|
|
| 27,918 |
|
|
Laboratory services |
|
| 2,406 |
|
|
| 2,280 |
|
|
| 8,017 |
|
|
| 6,798 |
|
|
Other product and service revenues |
|
| 576 |
|
|
| 141 |
|
|
| 1,235 |
|
|
| 752 |
|
|
Net product and services revenues |
|
| 53,229 |
|
|
| 46,749 |
|
|
| 165,549 |
|
|
| 105,972 |
|
|
Royalty income |
|
| 500 |
|
|
| 450 |
|
|
| 2,636 |
|
|
| 1,623 |
|
|
Other non-product revenues |
|
| 188 |
|
|
| 812 |
|
|
| 1,921 |
|
|
| 1,271 |
|
|
Other revenues |
|
| 688 |
|
|
| 1,262 |
|
|
| 4,557 |
|
|
| 2,894 |
|
|
Net revenues |
| $ | 53,917 |
|
| $ | 48,011 |
|
| $ | 170,106 |
|
| $ | 108,866 |
|
|
11
(1) 20202021 COVID-19, Genomics Microbiome, and COVID-19Microbiome revenues were reclassified to reflect the correct classification of the product line sales. The reclassification increased (decreased) the product line revenues for the three months ended SeptemberJune 30, 20202021 by $490, $(6584) and $(406), $(298), and $363, respectively andrespectively. The reclassification increased (decreased) the product line revenuerevenues for the ninesix months ended SeptemberJune 30, 20202021 by $1,073, $(157330) and $(743), $(respectively390), and $547, respectively..
Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:
|
| Three Months Ended September 30, |
|
| Nine Months Ended September 30, |
|
| Three Months Ended June 30, |
|
| Six Months Ended June 30, |
| |||||||||||||||||||||
|
| 2021 |
| 2020 |
|
| 2021 |
| 2020 |
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| |||||||||||
United States |
| $ | 42,969 |
|
| $ | 38,594 |
|
| $ | 139,669 |
|
| $ | 82,125 |
|
| $ | 70,320 |
|
| $ | 47,601 |
|
| $ | 128,307 |
|
| $ | 96,700 |
| |
Europe |
|
| 2,411 |
|
|
| 2,789 |
|
|
| 10,288 |
|
|
| 8,663 |
|
|
| 2,436 |
|
|
| 3,325 |
|
|
| 6,722 |
|
|
| 7,877 |
| |
Other regions |
|
| 8,537 |
|
|
| 6,628 |
|
|
|
| 20,149 |
|
|
| 18,078 |
|
|
| 7,475 |
|
|
| 6,681 |
|
|
| 12,909 |
|
|
| 11,612 |
|
|
| $ | 53,917 |
|
| $ | 48,011 |
|
|
| $ | 170,106 |
|
| $ | 108,866 |
|
| $ | 80,231 |
|
| $ | 57,607 |
|
| $ | 147,938 |
|
| $ | 116,189 |
|
Customer and Vendor Concentrations. At SeptemberJune 30, 2021,2022, one non-commercial customer accounted for 1348% of our accounts receivable and another commercial customer accounted for 10% of our accounts receivable. Another customerNo customers accounted for more than 1110% of our accounts receivable as of December 31, 2020.2021. One non-commercial customer accounted for 56% and 39% of net consolidated revenues for the three and six months ended June 30, 2022. One customer accounted for 14% of net consolidated revenues for the three months ended SeptemberJune 30, 2021. Another customer accounted for 10% of net consolidated revenues for the nine months ended September 30, 2021. One customer accounted forand 1114%, respectively, of net consolidated revenues for the three and six months ended SeptemberJune 30, 2020.2021.
We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Third-party suppliers also manufacture certain products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.
Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of SeptemberJune 30, 20212022 and December 31, 20202021 includes customer prepayments of $2,3401,746 and $3,2161,843, respectively. Deferred revenue as of SeptemberJune 30, 20212022 and December 31, 20202021 also includes $1,148914 and $1,5951,093, respectively, associated with a long-term contract that has variable pricing based on volume. The average price over the life of the contract was determined and revenue is recognized at that average price.
6. Goodwill
The following table represents the changes in goodwill by operating segment for the six months ended June 30, 2022:
11
|
| June 30, 2022 |
| |||||
|
| Diagnostics |
|
| Molecular Solutions |
| ||
Balance as of January 1 |
| $ | 3,604 |
|
| $ | 36,675 |
|
Impairment |
|
| (3,604 | ) |
|
| — |
|
Change related to foreign currency translation |
|
| — |
|
|
| (637 | ) |
Balance as of June 30 |
| $ | — |
|
| $ | 36,038 |
|
We perform an annual goodwill impairment assessment as of July 31 each year by comparing the estimated fair values of our reporting units to their respective carrying values. A more frequent evaluation is performed if an event occurs or circumstances change between annual tests that could more likely than not reduce the fair value of a reporting unit below its carrying amount.
During the three months ended June 30, 2022, we determined that a triggering event occurred in relation to the depressed market price of the Company's common stock and corresponding significant decline in our market capitalization. As a result, we performed an interim goodwill impairment test and concluded that the carrying value of our Diagnostics reporting unit exceeded its estimated fair value and the goodwill balance for that segment was fully impaired. Thus, we recognized a pre-tax impairment charge of $3.6 million during the three months ended June 30, 2022, which is reported in loss on impairments in our condensed consolidated statement of operations.
We estimated fair values of both of our reporting units using a combined income-based approach and market-based approach. Our income approach utilized projected future cash flows that were discounted at a rate of 22% for the Diagnostic reporting unit and 20% for the Molecular Solutions reporting unit based on a weighted-average cost of capital analysis that reflected current market conditions. The market comparable approach primarily considered earnings, revenue and other multiples of comparable companies and applied those multiples to certain key drivers of the reporting units. This market approach utilized a revenue multiple weighted by year for the Diagnostics reporting unit and both a revenue and EBITDA multiple for the Molecular Solutions reporting unit. We assigned a weight of 75% to the results of our income-based approach and 25% to the results from the market-based approach for estimation of the reporting units' fair value. Our fair value estimates utilize significant unobservable inputs and thus represent Level 3 fair value measurements.
7. Accrued Expenses and other current liabilities
|
| September 30, 2021 |
|
| December 31, 2020 |
| ||
Payroll and related benefits |
| $ | 13,728 |
|
| $ | 14,769 |
|
Professional fees |
|
| 1,831 |
|
|
| 978 |
|
Sales tax payable |
|
| 2,858 |
|
|
| 2,400 |
|
Other |
|
| 4,193 |
|
|
| 4,080 |
|
|
| $ | 22,610 |
|
| $ | 22,227 |
|
|
|
|
| |||||
|
| June 30, |
|
| December 31, |
| ||
Payroll and related benefits |
| $ | 11,636 |
|
| $ | 15,570 |
|
Commitment to purchase under government contract |
|
| — |
|
|
| 8,103 |
|
Deferred income for government contract |
|
| 620 |
|
|
| — |
|
Professional fees |
|
| 3,799 |
|
|
| 3,335 |
|
Sales tax payable |
|
| 1,807 |
|
|
| 2,227 |
|
Other |
|
| 5,303 |
|
|
| 4,543 |
|
|
| $ | 23,165 |
|
| $ | 33,778 |
|
8. Leases
We determine whether an arrangement is a lease at inception. We have operating and finance leases for corporate offices, warehouse space and equipment (including vehicles). As of SeptemberJune 30, 2021,2022, we are the lessee in all agreements. Our leases have remaining lease terms of 1 to 711 years, some of which include options to extend the leases based on agreed upon terms, and some of which include options to terminate the leases within 1 year.
As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.
We have lease agreements that contain both lease and non-lease components (e.g., common-area maintenance). For these agreements, we account for lease components separate from non-lease components.
12
The components of lease expense are as follows:
|
| Three Months Ended September 30, |
|
| Nine Months Ended September 30, |
| ||||||||||
|
| 2021 |
|
| 2020 |
|
| 2021 |
|
| 2020 |
| ||||
Operating Lease Cost |
| $ | 655 |
|
| $ | 330 |
|
| $ | 1,574 |
|
| $ | 964 |
|
Finance Lease Cost |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Amortization of right-of use assets |
|
| 571 |
|
|
| 150 |
|
|
| 910 |
|
|
| 476 |
|
Interest on lease liabilities |
|
| 49 |
|
|
| 17 |
|
|
| 84 |
|
|
| 56 |
|
Total Finance Lease Cost |
| $ | 620 |
|
| $ | 167 |
|
| $ | 994 |
|
| $ | 532 |
|
|
| Three Months Ended June 30, |
|
| Six Months Ended June 30, |
| ||||||||||
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||
Operating lease cost |
| $ | 811 |
|
| $ | 499 |
|
| $ | 1,510 |
|
| $ | 919 |
|
Variable and short-term lease cost |
|
| 152 |
|
|
| — |
|
|
| 227 |
|
|
| — |
|
Finance lease cost: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Amortization of right-of use assets |
|
| 306 |
|
|
| 212 |
|
|
| 691 |
|
|
| 339 |
|
Interest on lease liabilities |
|
| 23 |
|
|
| 21 |
|
|
| 55 |
|
|
| 35 |
|
Total finance lease cost |
|
| 329 |
|
|
| 233 |
|
|
| 746 |
|
|
| 374 |
|
Total lease cost |
| $ | 1,292 |
|
| $ | 732 |
|
| $ | 2,483 |
|
| $ | 1,293 |
|
Supplemental cash flow information related to leases is as follows:
|
| Nine Months Ended September 30, |
| |||||
|
| 2021 |
|
| 2020 |
| ||
Cash paid for amounts included in the measurement of lease liabilities: |
|
|
|
|
|
| ||
Operating cash flows from operating leases |
| $ | 1,182 |
|
| $ | 965 |
|
Operating cash flows from financing leases |
|
| 84 |
|
|
| 56 |
|
Financing cash flows from financing leases |
|
| 1,111 |
|
|
| 521 |
|
Non-cash activity: |
|
|
|
|
|
| ||
Right-of-use assets obtained in exchange for operating lease obligations |
|
| 45 |
|
|
| 498 |
|
Right-of-use assets obtained in exchange for finance lease obligations |
|
| 2,746 |
|
|
| 46 |
|
|
| Three Months Ended June 30, |
|
| Six Months Ended June 30, |
| ||||||||||
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||
Cash paid for amounts included in the measurement of lease liabilities: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Operating cash flows from operating leases |
| $ | 1,027 |
|
| $ | 416 |
|
| $ | 2,213 |
|
| $ | 824 |
|
Operating cash flows from financing leases |
|
| 23 |
|
|
| 21 |
|
|
| 55 |
|
|
| 35 |
|
Financing cash flows from financing leases |
|
| 239 |
|
|
| 228 |
|
|
| 392 |
|
|
| 510 |
|
Non-cash activity: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Right-of-use assets obtained in exchange for operating lease obligations |
|
| 5,131 |
|
|
| 7,205 |
|
|
| 8,797 |
|
|
| 7,834 |
|
Right-of-use assets obtained in exchange for finance lease obligations |
|
| - |
|
|
| — |
|
|
| 117 |
|
|
| — |
|
Supplemental balance sheet information related to leases is as follows:
|
| September 30, 2021 |
|
| December 31, 2020 |
| ||
Operating Leases |
|
|
|
|
|
| ||
Right-of-use assets |
| $ | 9,615 |
|
| $ | 4,461 |
|
|
|
|
|
|
|
| ||
Current lease liabilities |
|
| 2,178 |
|
|
| 1,125 |
|
Non-current lease liabilities |
|
| 7,740 |
|
|
| 3,591 |
|
Total operating lease liabilities |
| $ | 9,918 |
|
| $ | 4,716 |
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
| ||
Finance Leases |
|
|
|
|
|
| ||
Right-of-use assets |
| $ | 4,629 |
|
| $ | 1,312 |
|
|
|
|
|
|
|
| ||
Current lease liabilities |
|
| 1,912 |
|
|
| 517 |
|
Non-current lease liabilities |
|
| 2,834 |
|
|
| 895 |
|
Total finance lease liabilities |
| $ | 4,746 |
|
| $ | 1,412 |
|
| ||||
|
| |||
|
| |||
| ||||
|
|
| ||
|
|
|
|
|
|
| |||||
|
| June 30, 2022 |
|
| December 31, 2021 |
| ||
Operating Leases |
|
|
|
|
|
| ||
Right-of-use assets |
| $ | 16,451 |
|
| $ | 9,056 |
|
Lease liabilities: |
|
|
|
|
|
| ||
Current lease liabilities |
|
| 2,054 |
|
|
| 2,181 |
|
Non-current lease liabilities |
|
| 14,978 |
|
|
| 7,202 |
|
Total operating lease liabilities |
| $ | 17,032 |
|
| $ | 9,383 |
|
Finance Leases |
|
|
|
|
|
| ||
Right-of-use assets |
| $ | 1,887 |
|
| $ | 2,493 |
|
Lease liabilities: |
|
|
|
|
|
| ||
Current lease liabilities |
|
| 1,182 |
|
|
| 939 |
|
Non-current lease liabilities |
|
| 1,445 |
|
|
| 1,952 |
|
Total finance lease liabilities |
| $ | 2,627 |
|
| $ | 2,891 |
|
Weighted Average Remaining Lease Term |
|
|
|
|
|
| ||
Weighted-average remaining lease term—operating leases |
| 7.73 years |
|
| 5.26 years |
| ||
Weighted-average remaining lease term—finance leases |
| 1.82 years |
|
| 2.21 years |
| ||
|
|
|
|
|
|
| ||
Weighted Average Discount Rate |
|
|
|
|
|
| ||
Weighted-average discount rate—operating leases |
|
| 4.27 | % |
|
| 3.90 | % |
Weighted-average discount rate—finance leases |
|
| 3.52 | % |
|
| 3.57 | % |
13
As of SeptemberJune 30, 2021,2022, minimum lease payments by period are expected to be as follows:
|
|
|
|
|
| ||
| Finance |
|
| Operating |
| ||
2021 (excluding the nine months ended September 30, 2021) | $ | 510 |
|
| $ | 628 |
|
2022 |
| 2,040 |
|
|
| 2,493 |
|
2023 |
| 1,810 |
|
|
| 1,776 |
|
2024 |
| 582 |
|
|
| 1,808 |
|
2025 |
| 4 |
|
|
| 1,443 |
|
Thereafter |
| — |
|
|
| 2,808 |
|
Total Minimum Lease Payments |
| 4,946 |
|
|
| 10,956 |
|
Less: imputed interest |
| (200 | ) |
|
| (1,038 | ) |
Present Value of Lease Liabilities | $ | 4,746 |
|
| $ | 9,918 |
|
|
| Finance |
|
| Operating |
| ||
2022 (excluding the six months ended June 30, 2022) |
| $ | 710 |
|
| $ | 1,496 |
|
2023 |
|
| 1,283 |
|
|
| 1,879 |
|
2024 |
|
| 740 |
|
|
| 2,969 |
|
2025 |
|
| 19 |
|
|
| 2,619 |
|
2026 |
|
| 11 |
|
|
| 2,422 |
|
Thereafter |
|
| — |
|
|
| 9,021 |
|
Total minimum lease payments |
|
| 2,763 |
|
|
| 20,406 |
|
Less: imputed interest |
|
| (136 | ) |
|
| (3,374 | ) |
Present value of lease liabilities |
| $ | 2,627 |
|
| $ | 17,032 |
|
9.9. Stockholders’ Equity
Reconciliation of the changes in stockholders' equity for the three and six months ended June 30, 2022 and 2021 |
| |||||||||||||||||||||||
|
| Common Stock |
|
| Additional |
|
| Accumulated |
|
| Accumulated |
|
|
|
| |||||||||
|
| Shares |
|
| Amount |
|
| Capital |
|
| Loss |
|
| Deficit |
|
| Total |
| ||||||
Balance at December 31, 2021 |
|
| 72,069 |
|
| $ | — |
|
| $ | 511,063 |
|
| $ | (10,077 | ) |
| $ | (120,453 | ) |
| $ | 380,533 |
|
Common stock issued upon exercise of options |
|
| 2 |
|
|
| — |
|
|
| 15 |
|
|
| — |
|
|
| — |
|
|
| 15 |
|
Vesting of restricted stock and performance stock units |
|
| 352 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
Purchase and retirement of common shares |
|
| (116 | ) |
|
| — |
|
|
| (1,049 | ) |
|
| — |
|
|
| — |
|
|
| (1,049 | ) |
Stock-based compensation |
|
| — |
|
|
| — |
|
|
| 3,524 |
|
|
| — |
|
|
| — |
|
|
| 3,524 |
|
Net loss |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| (19,967 | ) |
|
| (19,967 | ) |
Currency translation adjustments |
|
| — |
|
|
| — |
|
|
| — |
|
|
| 1,756 |
|
|
| — |
|
|
| 1,756 |
|
Unrealized gain on marketable securities |
|
| — |
|
|
| — |
|
|
| — |
|
|
| 74 |
|
|
| — |
|
|
| 74 |
|
Balance at March 31, 2022 |
|
| 72,307 |
|
| $ | — |
|
| $ | 513,553 |
|
| $ | (8,247 | ) |
| $ | (140,420 | ) |
| $ | 364,886 |
|
Vesting of restricted stock and performance stock units |
|
| 407 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
Purchase and retirement of common shares |
|
| (142 | ) |
|
| — |
|
|
| (905 | ) |
|
| — |
|
|
| — |
|
|
| (905 | ) |
Stock-based compensation |
|
| — |
|
|
| — |
|
|
| 3,280 |
|
|
| — |
|
|
| — |
|
|
| 3,280 |
|
Net loss |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| (18,802 | ) |
|
| (18,802 | ) |
Currency translation adjustments |
|
| — |
|
|
| — |
|
|
| — |
|
|
| (4,349 | ) |
|
| — |
|
|
| (4,349 | ) |
Unrealized gain on marketable securities |
|
| — |
|
|
| — |
|
|
| — |
|
|
| 82 |
|
|
| — |
|
|
| 82 |
|
Balance at June 30, 2022 |
|
| 72,572 |
|
| $ | — |
|
| $ | 515,928 |
|
| $ | (12,514 | ) |
| $ | (159,222 | ) |
| $ | 344,192 |
|
Reconciliation of the changes in stockholders' equity for the three and nine months ended September 30, 2021 and 2020 |
| |||||||||||||||||||||||
|
| Common Stock |
|
| Additional |
|
| Accumulated |
|
| Accumulated |
|
|
|
| |||||||||
|
| Shares |
|
| Amount |
|
| Capital |
|
| Loss |
|
| Deficit |
|
| Total |
| ||||||
Balance at December 31, 2020 |
|
| 71,738 |
|
| $ | — |
|
| $ | 505,123 |
|
| $ | (9,097 | ) |
| $ | (97,455 | ) |
| $ | 398,571 |
|
Common stock issued upon exercise of options |
|
| 11 |
|
|
| — |
|
|
| 92 |
|
|
| — |
|
|
| — |
|
|
| 92 |
|
Vesting of restricted stock and performance stock units |
|
| 318 |
|
|
| — |
|
|
|
|
|
| — |
|
|
| — |
|
|
| — |
| |
Purchase and retirement of common shares |
|
| (111 | ) |
|
| — |
|
|
| (1,730 | ) |
|
| — |
|
|
| — |
|
|
| (1,730 | ) |
Stock-based compensation |
|
| — |
|
|
| — |
|
|
| 1,464 |
|
|
| — |
|
|
| — |
|
|
| 1,464 |
|
Net income |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 3,774 |
|
|
| 3,774 |
|
Currency translation adjustments |
|
| — |
|
|
| — |
|
|
| — |
|
|
| 1,352 |
|
|
| — |
|
|
| 1,352 |
|
Unrealized gain on marketable securities |
|
| — |
|
|
| — |
|
|
| — |
|
|
| 21 |
|
|
| — |
|
|
| 21 |
|
Balance at March 31, 2021 |
|
| 71,956 |
|
| $ | — |
|
| $ | 504,949 |
|
| $ | (7,724 | ) |
| $ | (93,681 | ) |
| $ | 403,544 |
|
Common stock issued upon exercise of options |
|
| 3 |
|
|
| — |
|
|
| 29 |
|
|
| — |
|
|
| — |
|
|
| 29 |
|
Vesting of restricted stock and performance stock units |
|
| 64 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
Purchase and retirement of common shares |
|
| (15 | ) |
|
| — |
|
|
| (147 | ) |
|
| — |
|
|
| — |
|
|
| (147 | ) |
Stock-based compensation |
|
| — |
|
|
| — |
|
|
| 1,473 |
|
|
| — |
|
|
| — |
|
|
| 1,473 |
|
Net loss |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| (1,364 | ) |
|
| (1,364 | ) |
Currency translation adjustments |
|
| — |
|
|
| — |
|
|
| — |
|
|
| 1,403 |
|
|
| — |
|
|
| 1,403 |
|
Unrealized loss on marketable securities |
|
| — |
|
|
| — |
|
|
| — |
|
|
| (122 | ) |
|
| — |
|
|
| (122 | ) |
Balance at June 30, 2021 |
|
| 72,008 |
|
| $ | — |
|
| $ | 506,304 |
|
| $ | (6,443 | ) |
| $ | (95,045 | ) |
| $ | 404,816 |
|
Common stock issued upon exercise of options |
|
| 18 |
|
|
| — |
|
|
| 126 |
|
|
| — |
|
|
| — |
|
|
| 126 |
|
Vesting of restricted stock and performance stock units |
|
| 16 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
Purchase and retirement of common shares |
|
| (4 | ) |
|
| — |
|
|
| (47 | ) |
|
| — |
|
|
| — |
|
|
| (47 | ) |
Stock-based compensation |
|
| — |
|
|
| — |
|
|
| 2,218 |
|
|
| — |
|
|
| — |
|
|
| 2,218 |
|
Net loss |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| (15,015 | ) |
|
| (15,015 | ) |
Currency translation adjustments |
|
| — |
|
|
| — |
|
|
| — |
|
|
| (4,117 | ) |
|
| — |
|
|
| (4,117 | ) |
Unrealized loss on marketable securities |
|
| — |
|
|
| — |
|
|
| — |
|
|
| (161 | ) |
|
| — |
|
|
| (161 | ) |
Balance at September 30, 2021 |
|
| 72,038 |
|
| $ | — |
|
| $ | 508,601 |
|
| $ | (10,721 | ) |
| $ | (110,060 | ) |
| $ | 387,820 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
| Common Stock |
|
| Additional |
|
| Accumulated |
|
| Accumulated |
|
|
|
| |||||||||
|
| Shares |
|
| Amount |
|
| Capital |
|
| Loss |
|
| Deficit |
|
| Total |
| ||||||
Balance at December 31, 2019 |
|
| 61,731 |
|
| $ | — |
|
| $ | 401,814 |
|
| $ | (12,136 | ) |
| $ | (82,533 | ) |
| $ | 307,145 |
|
14
Common stock issued upon exercise of options |
|
| 6 |
|
|
| — |
|
|
| 30 |
|
|
| — |
|
|
| — |
|
|
| 30 |
|
Vesting of restricted stock and performance stock units |
|
| 486 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
Purchase and retirement of common shares |
|
| (197 | ) |
|
| — |
|
|
| (1,408 | ) |
|
| — |
|
|
| — |
|
|
| (1,408 | ) |
Stock-based compensation |
|
| — |
|
|
| — |
|
|
| 1,376 |
|
|
| — |
|
|
| — |
|
|
| 1,376 |
|
Net loss |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| (7,328 | ) |
|
| (7,328 | ) |
Currency translation adjustments |
|
| — |
|
|
| — |
|
|
| — |
|
|
| (9,221 | ) |
|
| — |
|
|
| (9,221 | ) |
Unrealized loss on marketable securities |
|
| — |
|
|
| — |
|
|
| — |
|
|
| (442 | ) |
|
| — |
|
|
| (442 | ) |
Balance at March 31, 2020 |
|
| 62,026 |
|
| $ | — |
|
| $ | 401,812 |
|
| $ | (21,799 | ) |
| $ | (89,861 | ) |
| $ | 290,152 |
|
Common stock issued upon exercise of options |
|
| 71 |
|
|
| — |
|
|
| 530 |
|
|
| — |
|
|
| — |
|
|
| 530 |
|
Vesting of restricted stock and performance stock units |
|
| 161 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
Purchase and retirement of common shares |
|
| (50 | ) |
|
| — |
|
|
| (656 | ) |
|
| — |
|
|
| — |
|
|
| (656 | ) |
Issuance of common stock in connection with public offering, net of commissions and expenses of $6,200 |
|
| 9,200 |
|
|
|
|
|
| 95,036 |
|
|
|
|
|
|
|
|
| 95,036 |
| |||
Stock-based compensation |
|
| — |
|
|
| — |
|
|
| 2,672 |
|
|
| — |
|
|
| — |
|
|
| 2,672 |
|
Net loss |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| (10,494 | ) |
|
| (10,494 | ) |
Currency translation adjustments |
|
| — |
|
|
| — |
|
|
| — |
|
|
| 3,726 |
|
|
| — |
|
|
| 3,726 |
|
Unrealized gain on marketable securities |
|
| — |
|
|
| — |
|
|
| — |
|
|
| 791 |
|
|
| — |
|
|
| 791 |
|
Balance at June 30, 2020 |
|
| 71,408 |
|
| $ | — |
|
| $ | 499,394 |
|
| $ | (17,282 | ) |
| $ | (100,355 | ) |
| $ | 381,757 |
|
Common stock issued upon exercise of options |
|
| 202 |
|
|
| — |
|
|
| 1,555 |
|
|
| — |
|
|
| — |
|
|
| 1,555 |
|
Vesting of restricted stock and performance stock units |
|
| 2 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
Purchase and retirement of common shares |
|
| (1 | ) |
|
| — |
|
|
| (12 | ) |
|
| — |
|
|
| — |
|
|
| (12 | ) |
Stock-based compensation |
|
| — |
|
|
| — |
|
|
| 1,865 |
|
|
| — |
|
|
| — |
|
|
| 1,865 |
|
Net income |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 1,040 |
|
|
| 1,040 |
|
Currency translation adjustments |
|
| — |
|
|
| — |
|
|
| — |
|
|
| 1,953 |
|
|
| — |
|
|
| 1,953 |
|
Unrealized loss on marketable securities |
|
| — |
|
|
| — |
|
|
| — |
|
|
| (266 | ) |
|
| — |
|
|
| (266 | ) |
Balance at September 30, 2020 |
|
| 71,611 |
|
| $ | — |
|
| $ | 502,802 |
|
| $ | (15,595 | ) |
| $ | (99,315 | ) |
| $ | 387,892 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
| Common Stock |
|
| Additional |
|
| Accumulated |
|
| Accumulated |
|
|
|
| |||||||||
|
| Shares |
|
| Amount |
|
| Capital |
|
| Loss |
|
| Deficit |
|
| Total |
| ||||||
Balance at December 31, 2020 |
|
| 71,738 |
|
| $ | — |
|
| $ | 505,123 |
|
| $ | (9,097 | ) |
| $ | (97,455 | ) |
| $ | 398,571 |
|
Common stock issued upon exercise of options |
|
| 11 |
|
|
| — |
|
|
| 92 |
|
|
| — |
|
|
| — |
|
|
| 92 |
|
Vesting of restricted stock and performance stock units |
|
| 318 |
|
|
| — |
|
|
|
|
|
| — |
|
|
| — |
|
|
| — |
| |
Purchase and retirement of common shares |
|
| (111 | ) |
|
| — |
|
|
| (1,730 | ) |
|
| — |
|
|
| — |
|
|
| (1,730 | ) |
Stock-based compensation |
|
| — |
|
|
| — |
|
|
| 1,464 |
|
|
| — |
|
|
| — |
|
|
| 1,464 |
|
Net income |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| 3,774 |
|
|
| 3,774 |
|
Currency translation adjustments |
|
| — |
|
|
| — |
|
|
| — |
|
|
| 1,352 |
|
|
| — |
|
|
| 1,352 |
|
Unrealized gain on marketable securities |
|
| — |
|
|
| — |
|
|
| — |
|
|
| 21 |
|
|
| — |
|
|
| 21 |
|
Balance at March 31, 2021 |
|
| 71,956 |
|
| $ | — |
|
| $ | 504,949 |
|
| $ | (7,724 | ) |
| $ | (93,681 | ) |
| $ | 403,544 |
|
Common stock issued upon exercise of options |
|
| 3 |
|
|
| — |
|
|
| 29 |
|
|
| — |
|
|
| — |
|
|
| 29 |
|
Vesting of restricted stock and performance stock units |
|
| 64 |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
Purchase and retirement of common shares |
|
| (15 | ) |
|
| — |
|
|
| (147 | ) |
|
| — |
|
|
| — |
|
|
| (147 | ) |
Stock-based compensation |
|
| — |
|
|
| — |
|
|
| 1,473 |
|
|
| — |
|
|
| — |
|
|
| 1,473 |
|
Net loss |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| (1,364 | ) |
|
| (1,364 | ) |
Currency translation adjustments |
|
| — |
|
|
| — |
|
|
| — |
|
|
| 1,403 |
|
|
| — |
|
|
| 1,403 |
|
Unrealized loss on marketable securities |
|
| — |
| �� |
| — |
|
|
| — |
|
|
| (122 | ) |
|
| — |
|
|
| (122 | ) |
Balance at June 30, 2021 |
|
| 72,008 |
|
| $ | — |
|
| $ | 506,304 |
|
| $ | (6,443 | ) |
| $ | (95,045 | ) |
| $ | 404,816 |
|
Stock-Based Awards
We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. We account for stock-based compensation to employees and directors using the fair value method. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. We recognize compensation expense related to performance-based restricted stock units based on assumptions as to what percentage of each performance target will be achieved. We evaluate these target assumptions on a quarterly basis and adjust compensation expense related to these awards, as appropriate. To satisfy the exercise of options, issuance of restricted stock, or redemption of performance-based restricted stock units, we issue new shares rather than shares purchased on the open market.
Total compensation costexpense related to stock options for the ninesix months ended SeptemberJune 30, 20212022 and 20202021 was $793879 and $683521, respectively.
The following table summarizes the stock option activity for the six months ended June 30, 2022:
Options | |||||
Outstanding on January 1, 2022 | 1,410 | ||||
Granted | 589 | ||||
Exercised | (2 | ) | |||
Expired | (20 | ) | |||
Forfeited | (173 | ) | |||
Outstanding on June 30, 2022 | 1,804 |
Compensation costexpense of $2,8915,071 and $3,3292,066 related to restricted shares was recognized during the ninesix months ended SeptemberJune 30, 20212022 and 2020,2021, respectively.
The following table summarizes time-vested restricted stock award and restricted stock unit activity for the six months ended June 30, 2022:
15
Units | |||||
Issued and unvested, January 1, 2022 | 701 | ||||
Granted | 2,782 | ||||
Vested | (571 | ) | |||
Forfeited | (249 | ) | |||
Issued and unvested, June 30, 2022 | 2,663 |
We grant performance-based restricted stock units (“PSUs”) to certain executives. Vesting of these PSUs is dependent upon achievement of certain performance-based metrics during a one-year or three-year period from the date of grant. Assuming achievement of each performance-based metric, the executive must also generally remain employed for three years from the grant date. If the one-year target is achieved, the PSUs will then vest three years from grant date. If the three-year target is achieved, the corresponding PSUs will then vest three years from grant date. PSUs are converted into shares of our common stock once vested.
Compensation costexpense of $1,471854 and $1,901350 related to PSUs was recognized during the ninesix months ended SeptemberJune 30, 20212022 and 2020,2021, respectively.
15The following table summarizes the PSU activity for the six months ended June 30, 2022:
Public Offering
Units | |||||
Issued and unvested, January 1, 2022 | 622 | ||||
Granted (1) | 532 | ||||
Performance adjustment (2) | 36 | ||||
Vested | (188 | ) | |||
Forfeited | (171 | ) | |||
Issued and unvested, June 30, 2022 | 831 |
On June 1, 2020, we entered into an underwriting agreement with J.P. Morgan Securities LLC, Citigroup Global Markets Inc. and Evercore Group LLC, as representatives of several underwriters, relating to(1) Grant activity for all PSUs disclosed at target
(2) Reflects the issuance and sale of 8,000 shares of our common stock. The price toperformance adjustment based on actual performance measured at the public in the offering was $11.00 per share. Under the termsend of the underwriting agreement, we also granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 1,200 shares of common stock. On June 3, 2020, we announced the full exercise by the underwriters of their option to purchase these additional shares.performance period
The offering was made pursuant to an effective registration statement on Form S-3 (File No. 333-228877) we had previously filed with the SEC, and a prospectus supplement thereunder. The net proceeds from the offering were approximately $95,000 after deducting underwriting discounts and offering expenses paid by the Company.
Stock Repurchase Program
On August 5, 2008, our Board of Directors approved a share repurchase program pursuant to which we are permitted to acquire up to $25,000 of our outstanding common shares. NaN shares were purchased and retired during the ninesix months ended SeptemberJune 30, 20212022 and 2020.2021.
10.Transition costs
On December 31, 2021, the Company's Board of Directors approved the termination of Stephen S. Tang, the Company’s former President and Chief Executive Officer, without cause under his existing employment agreement with the Company, with such termination effective as of March 31, 2022. On January 2, 2022, Dr. Tang and the Company entered into a transition agreement ("Transition Agreement") providing for the terms of the cessation of Dr. Tang’s employment with the Company, including the cessation of his service as President and Chief Executive Officer of the Company and as a member of the Board. Dr. Tang’s service to the Company in all capacities ended on March 31, 2022.
Pursuant to the Transition Agreement, Dr. Tang received severance of $1,569, which was accrued in the consolidated financial statements at December 31, 2021 and paid in April 2022. Additionally, in accordance with his Transition Agreement, certain of his unvested time-vesting restricted stock awards and unvested PSUs that were outstanding at March 31, 2022 vested on April 8, 2022. His remaining unvested time-vesting restricted stock awards and PSUs were forfeited on March 31, 2022. These payments, rights and benefits are substantially similar to the severance benefits contemplated by his previous employment agreement in respect to a termination without cause thereunder. In aggregate, we recognized a net $128 and $1,508 of expense in relation to Dr. Tang's stock compensation during the three and six months ended June 30, 2022, respectively.
On April 1, 2022 the Company's Board of Directors appointed Nancy J. Gagliano, M.D., M.B.A., to serve as the Company’s Interim Chief Executive Officer. In connection therewith, the Company and Dr. Gagliano entered into an employment agreement, dated as of March 21, 2022 (the “Employment Agreement”). Pursuant to the Employment Agreement, on April 1, 2022, Dr. Gagliano began receiving a monthly base salary of $56 per month and was also granted a one-time award of fully vested shares of the Company’s common stock with a grant date fair value of $100. Additionally, she was granted a one-time restricted stock unit award with a grant date fair value of $670 scheduled to vest in twelve equal monthly installments starting in April through her employment term, of which $168 vested during the three months ended June 30, 2022 and the remainder was forfeited when her employment ceased in June 2022.
16
On May 20, 2022, the Company entered into an employment agreement with Carrie Eglinton Manner, and in connection therewith, the Company's Board of Directors appointed Ms. Eglinton Manner as the Company’s President and Chief Executive Officer, effective June 4, 2022 (the “Effective Date”). Pursuant to the Employment Agreement, Ms. Eglinton Manner’s initial annual base salary is $700 and she will participate in the Company’s annual incentive plan with a target annual incentive amount of at least 100% of her annual base salary. Additionally, she received inducement grants comprised of (i) a restricted stock unit award with a grant date fair value of $4,000, which vests on the second anniversary of the Effective Date (ii) a restricted stock award with a grant date fair value of $1,600, which vests annually starting on the first anniversary of the Effective Date and (iii) a PSU award with a grant date fair value of $1,600, which will be subject to the same vesting and performance conditions as are applicable to the 2022 performance-based restricted stock unit awards granted to the Company’s other executive officers.
11. Income Taxes
During the three and ninesix months ended SeptemberJune 30, 2022, we recorded an income tax expense (benefit) of $(1,169) and $2,767, respectively. Tax expense for 2022 includes $1,702 of withholding tax due on the repatriation of $65,000 of unremitted earnings from Canada to the United States. The remaining tax expense for the first half of 2022 is comprised of U.S. state income taxes of $400 and foreign taxes of $665. During the three and six months ended June 30, 2021, we recorded income tax expense of $2,1023,610 and $12,24110,139, respectively, which primarily consistedconsists of foreign tax expense. During the three and nine months ended September 30, 2020, we recorded income tax expense of $3,659 and $5,680, respectively, which also primarily consisted of a foreign tax expense.
Tax expense reflects taxes due to the taxing authorities and the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting and tax purposes, and net operating loss and tax credit carryforwards. The significant components of our total deferred tax liability as of SeptemberJune 30, 20212022 and December 31, 20202021 relate to the tax effects of the basis difference between the intangible assets acquired in our acquisitions for financial reporting and for tax purposes along with basis differences arising from accelerated tax depreciation of fixed assets.
In 2008, we established a full valuation allowance against our U.S. deferred tax asset. Management believes the full valuation allowance is still appropriate at both SeptemberJune 30, 20212022 and December 31, 20202021 since the facts and circumstances necessitating the allowance have not changed.
11.12. Commitments and Contingencies
Litigation
Litigation
From time to time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, the outcomes of such actions, either individually or in the aggregate, are not expected to have a material adverse effect on our future financial position or results of operations.
In March 2021, we filed a complaint against Spectrum Solutions, LLC ("Spectrum") in the United States District Court for the Southern District of California alleging that certain saliva collection devices manufactured and sold by Spectrum infringe a patent held by DNAG. Spectrum has filed an answer to the initial complaint, asserting that its device does not infringe our patent and that our patent is invalid. In August 2021, we amended our complaint to add a second patent to this litigation. Spectrum responded to our amended complaint and asserted counterclaims for inequitable conduct and antitrust violations with respect to one of the patents in the litigation. We believe Spectrum's counterclaims are without merit and weDNAG filed a motion to dismiss both claimsSpectrum’s counterclaims in October 2021. We are seeking injunctive relief and damages in this matter.
Commitments
As of2021, which was denied by the Court on March 30, 2022. The final pretrial conference is set for September 30, 2021, we have entered in several new contracts associated with the manufacture and supply of our COVID-19 antigen products and our molecular collection solutions products that include unconditional commitments to purchase certain materials through the latest of the first quarter of 2026 in the aggregate amount of $126,499.7, 2023.
16
12.13. Business Segment Information
Our business consists of 2 segments: our “Diagnostics” business, which primarily consists of the development, manufacture, marketing and sale of rapid diagnostic tests used to determine if a person has a variety of infectious diseases including, HIV, HCV, and COVID-19. The Diagnostic business also manufactures and sells oral fluid diagnostic products and specimen collection devices using our proprietary technologies, other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our Diagnostics segment includes the financial results of UrSure.substance abuse testing products. Our “Molecular Solutions” business is operated by our wholly-owned subsidiaries DNAG, Diversigen, and Novosanis. This segment of the business consists of the development, manufacture, marketing and sale of specimen collection kits that are used to collect, stabilize, transport and store samplesa biological sample of genetic material for molecular testing. Our collection kits are also used for the collection of first-void urine for liquid biopsy in the prostate and bladder cancer markets; and in the sexually transmitted infection screening market. In addition, our Molecular Solutions business provides microbiome laboratory services that accelerate research and discovery for customers in the pharmaceutical, agricultural, and academic research markets. Financial results of Diversigen and Novosanis are included in our Molecular Solutions segment.services.
We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2)1). We evaluate performance of our operating segments based on revenue and operating income. We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues and inter-segment expenses have been eliminated.
17
The following table summarizes operating segment information for the three and ninesix months ended SeptemberJune 30, 20212022 and 2020,2021, and asset information as of SeptemberJune 30, 20212022 and December 31, 2020:2021:
|
| Three Months Ended September 30, |
| Nine Months Ended September 30, |
|
| Three Months Ended June 30, |
|
| Six Months Ended June 30, |
| |||||||||||||||||||||
|
| 2021 |
| 2020 |
| 2021 |
| 2020 |
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| |||||||||||
Net revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Diagnostics |
| $ | 23,511 |
|
| $ | 16,314 |
| $ | 57,368 |
|
| $ | 44,533 |
|
| $ | 60,455 |
|
| $ | 19,311 |
|
| $ | 98,765 |
|
| $ | 33,857 |
| |
Molecular Solutions |
|
| 30,406 |
|
|
| 31,697 |
|
| 112,738 |
|
|
| 64,333 |
|
|
| 19,776 |
|
|
| 38,296 |
|
|
| 49,173 |
|
|
| 82,332 |
| |
Total |
| $ | 53,917 |
|
| $ | 48,011 |
| $ | 170,106 |
|
| $ | 108,866 |
|
| $ | 80,231 |
|
| $ | 57,607 |
|
| $ | 147,938 |
|
| $ | 116,189 |
| |
Operating income (loss): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
Diagnostics |
| $ | (18,638 | ) |
| $ | (9,951 | ) |
| $ | (42,755 | ) |
| $ | (31,116 | ) |
| $ | (11,776 | ) |
| $ | (11,850 | ) |
| $ | (31,563 | ) |
| $ | (23,967 | ) |
Molecular Solutions |
|
| 5,625 |
|
|
| 14,336 |
|
| 41,962 |
|
|
| 18,054 |
|
|
| (9,513 | ) |
|
| 13,648 |
|
|
| (5,704 | ) |
|
| 36,187 |
| |
Total |
| $ | (13,013 | ) |
| $ | 4,385 |
| $ | (793 | ) |
| $ | (13,062 | ) |
| $ | (21,289 | ) |
| $ | 1,798 |
|
| $ | (37,267 | ) |
| $ | 12,220 |
| |
Depreciation and amortization: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Diagnostics |
| $ | 1,136 |
|
| $ | 934 |
| $ | 2,965 |
|
| $ | 2,448 |
|
| $ | 1,903 |
|
| $ | 939 |
|
| $ | 3,630 |
|
| $ | 1,829 |
| |
Molecular Solutions |
|
| 2,199 |
|
|
| 1,517 |
|
| 5,514 |
|
|
| 4,432 |
|
|
| 1,879 |
|
|
| 1,716 |
|
|
| 3,834 |
|
|
| 3,315 |
| |
Total |
| $ | 3,335 |
|
| $ | 2,451 |
| $ | 8,479 |
|
| $ | 6,880 |
|
| $ | 3,782 |
|
| $ | 2,655 |
|
| $ | 7,464 |
|
| $ | 5,144 |
| |
Capital expenditures: |
|
|
|
|
|
|
|
|
|
| ||||||||||||||||||||||
Loss on impairment: |
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||
Diagnostics |
| $ | 3,647 |
|
| $ | 2,186 |
| $ | 19,797 |
|
| $ | 5,634 |
|
| $ | 8,517 |
|
| $ | — |
|
| $ | 8,517 |
|
| $ | — |
| |
Molecular Solutions |
|
| 932 |
|
|
| 3,011 |
|
| 7,711 |
|
|
| 5,600 |
|
|
| 2,025 |
|
|
| — |
|
|
| 2,025 |
|
|
| — |
| |
Total |
| $ | 4,579 |
|
| $ | 5,197 |
| $ | 27,508 |
|
| $ | 11,234 |
|
| $ | 10,542 |
|
| $ | — |
|
| $ | 10,542 |
|
| $ | — |
| |
Capital expenditures: |
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||
Diagnostics(1) |
| $ | 4,302 |
|
| $ | 8,513 |
|
| $ | 23,434 |
|
| $ | 16,150 |
| ||||||||||||||||
Molecular Solutions |
|
| 919 |
|
|
| 3,355 |
|
|
| 2,006 |
|
|
| 6,779 |
| ||||||||||||||||
Total |
| $ | 5,221 |
|
| $ | 11,868 |
|
| $ | 25,440 |
|
| $ | 22,929 |
|
(1)Excludes $5,615 and $33,803 for purchases of property and equipment under government contracts for the three and six months ended June 30, 2022, respectively.
|
| September 30, 2021 |
| December 31, 2020 |
|
| June 30, |
|
| December 31, |
| |||||
Total assets: |
|
|
|
|
|
|
|
|
|
| ||||||
Diagnostics |
| $ | 206,668 |
|
| $ | 242,613 |
|
| $ | 249,123 |
|
| $ | 209,674 |
|
Molecular Solutions |
|
| 249,089 |
|
|
| 211,859 |
|
|
| 180,131 |
|
|
| 251,316 |
|
Total |
| $ | 455,757 |
|
| $ | 454,472 |
|
| $ | 429,254 |
|
| $ | 460,990 |
|
1718
Item 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Statements below regarding future events or performance are “forward-looking statements” within the meaning of the Federal securities laws. These may include statements about our expected revenues, earnings, losses, expenses, or other financial performance, future product performance or development, expected regulatory filings and approvals, planned business transactions, expected manufacturing performance, views of future industry, competitive or market conditions, and other factors that could affect our future operations, results of operations or financial position. These statements often include words such as “believes,” “expects,” “anticipates,” “intends,” “plans,” “estimates,” “may,” “will,” “should,” “could,” or similar expressions. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: ability of the Company to manufacture sufficient quantities of the InteliswabTM
19
These and other factors that could affect our results are discussed more fully in our Securities and Exchange Commission (“SEC”) filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2020,2021, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this Report, and we undertake no duty to update these statements.
Investors should also be aware that while we do, from time to time, communicate with securities analysts, it is against our policy to disclose any material non-public information or other confidential commercial information. Accordingly, stockholders should not assume that we agree with any statement or report issued by any analyst irrespective of the content of the statement or report. Furthermore, we have a policy against issuing or confirming financial forecasts or projections issued by others. Thus, to the extent that reports issued by securities analysts contain any projections, forecasts or opinions, such reports are not the responsibility of OraSure.
The following discussion should be read in conjunction with our consolidated financial statements contained herein and the notes thereto, along with the Section entitled “Critical Accounting Policies and Estimates,” set forth below.
1820
Overview and Business Segments
The overall goal of our Company is to empower the global community to improve health and wellness by providing access to accurate essential information. Our business consists of two segments: our “Diagnostics” segment and our “Molecular Solutions” segment.
Our Diagnostics business primarily consists of the development, manufacture, marketing and sale of oral fluidsimple, easy to use diagnostic products and specimen collection devices using our proprietary technologies, as well as other diagnostic products including immunoassays and other in vitrodiagnostic tests that are used on other specimen types. The Diagnostics business includes tests for diseases including COVID-19, HIV and Hepatitis C that are performed on a rapid basis at the point of care, and tests for drugs of abuse that are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Our COVID-19 and HIV product isproducts are also sold in a consumer-friendly format in the OTCover-the-counter (“OTC”) market in the U.S. and, in the case of the HIV product, as a self-test to individuals in a number of other countries. OurThrough our Diagnostics business includes the operations of UrSure, which was acquiredwe are also developing and merged into OraSure in 2020. This part of the Diagnostics business develops and commercializescommercializing products that measure adherence to HIV medications including pre-exposure prophylaxis or PrEP,("PrEP"), the daily medication to prevent HIV, and anti-retroviral medications to suppress HIV. These products include laboratory-based tests that can measure levels of the medicationmedications in a patient’s urine or blood, as well as point- of-carepoint-of-care products currently in development. We began recording revenues on the sales of our InteliSwab®COVID-19 Rapid Tests during the third quarter of 2021.
Our Molecular Solutions business is operated by our wholly-owned subsidiaries, DNAG,DNA Genotek, Inc. ("DNAG"), Diversigen, Inc. ('Diversigen"), and Novosanis. In thisNovosanis NV ("Novosanis"). Our Molecular Solutions business we manufacturesells its products and sell kits that are usedservices directly to collect, stabilize, transportits customers, primarily through its internal sales force in the U.S. domestic market, and store a biological sample of genetic material for molecular testing.in many international markets, also through distributors. Our products areprimarily consist of collection kits and services used for academic research and commercial applications, including ancestry, disease risk management, lifestyleby clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal testing. Includedhealth service and product providers. Most of our Molecular Solutions revenues are derived from product sales to commercial customers and sales into the academic and research markets. A significant portion of our total sales is from repeat customers in both markets. Molecular Solutions customers span the disease risk management, area are pharmacogenomics testing, hereditary disease screening, prenatal or cancer screening, population health initiativesdiagnostics, pharmaceutical, biotech, companion animal and other molecular testing using DNA or RNA for diagnosisenvironmental markets.
We have expanded the market focus of acute disease. We also sell research-use-onlyour Molecular Solutions business by selling existing collection products intofor use with COVID-19 tests. Demand for COVID-19 PCR testing has declined driven by the availability of antigen tests and the wider availability of vaccines, thereby negatively impacting the sales of the collection products. We have also developed new collection devices for the emerging microbiome market, which focuses on studying microbes and their effect on human health. Our primary product offering in the microbiome market.market, OMNIgene® • GUT, is focused on the human gut microbiome (microbes living in human stool). In 2021, the OMNIgene® • GUT collection device (OMD-200) was granted “FDA De Novo classification for the preservation and stabilization of the relative abundance of microbial nucleic acids in clinical samples.” We offerleverage our existing sales force and global research connections to engage microbiome customers a suiteworldwide to establish ourselves among the leaders in ease-of-collection, stabilization, and transport of genomics and microbiome services that range from package customization and study design optimization to extraction, analysis and reporting services. The microbiome laboratory and bioinformatics services are provided by Diversigen, whichthis challenging sample type.
Our Molecular Solutions segment includes the operations of CoreBiome, aColli-Pee® device, developed and sold by our Novosanis subsidiary, we acquired in early 2019. CoreBiome and Diversigen were merged together in 2020. Novosanis manufactures and sells the Colli-Pee® collection device for the volumetric collection of first-void urine for usefirst void urine. This product is in research, screeningits early stages, and diagnosticsinitial sales are occurring primarily through distributors and collaborations in the liquid biopsy and sexually transmitted infectiondisease markets. Our Molecular Solutions business servesalso offers laboratory and analytical services for both genomics and microbiome customers in many countries worldwide, including many leadingto more fully meet their needs. These services are primarily provided to pharmaceutical, biotech companies, and research universities and hospitals.institutions.
Recent Developments
Impact of COVID-19
TheAs COVID-19 pandemic continues to impact the economy of the United States and other countries around the world, we are committed to being a part of the response to this unprecedented challenge. We have made substantial investments to expand our operations in order to manufacture product used for COVID-19 testing in the United States.
Due to COVID-19, we have experienced volatility, including periods of material decline compared to prior year periods in testing volume of our base business operations(which excludes COVID-19 testing) and itperiods of significant demand for our COVID-19 testing product, with demand generally fluctuating in line with changes in prevalence of the virus and related variants. It is not possibledifficult for us to predict the duration or magnitude of the outbreak’s effects on our business or results of operations. During 2020, traditional HIV and HCV testing programs and drug testing in the workplace market were reduced or terminated as a result of the various “stay-at-home” orders and social distancing guidelines issued by federal, state and local governments to contain the spread of the COVID-19 pandemic and we continued to see this impact our business in early 2021. However, during the second and third quarters of 2021, we saw a resumption of HIV and HCV testing in the U.S. as domestic sales of our non-COVID diagnostic products began returning to pre-pandemic levels. On the international front, professional HIV and HCV testing in Europe and Asia also started to pick up. However, more recently we have experienced reductions and stoppages of HIV self-testing in Southern and Eastern African countries due to the COVID-19 pandemic. In our Molecular Solutions segment, COVID-related disruption in clinical and research work, particularly in the academic market, had reduced demand for our products in 2020 and early 2021, but demand levels started to return to normal in the second and third quarters of 2021. Although the negative trends that materially impacted our results of operations during 2020 and early 2021 are starting to abate, it is impossible to predict if this improvement will continue and these negative trends may adversely impact certain parts of our business in future periods and for an indeterminate time period, depending on the duration and severity of the COVID-19 pandemic, the impact of COVID-19 variants and the scope and success of vaccination programs globally.
We also have experienced significant opportunities, and continue to believe there are potentially more significant opportunities, for increased revenues as a result of the COVID-19 pandemic. In 2020, we began selling our saliva collection devices for use in molecular COVID-19 testing. In the first nine months of 2021, we generated revenues of approximately $46.2 million from sales of our molecular collection devices related to COVID-19 testing. In the U.S., public health customers purchased increased quantities of our OraQuick® In-Home HIV Test in order to permit continued HIV testing while allowing clients and patients to adhere to “stay-at-home” and social distancing requirements. In addition, we saw increased demand for our molecular collection products from customers who conduct both saliva and blood-based testing. As it became more difficult to collect blood in clinics or healthcare settings, these customers increasingly relied on the saliva collection alternative. However, demand for molecular COVID-19 testing during the second and third quarters of 2021 began to decline primarily due to the availability of vaccines. We believe this trend will continue in future periods.
In June 2021, we received three Emergency Use Authorizations ("EUAs") from the U.S. Food and Drug Administration ("FDA") for our InteliSwabTM COVID-19 Rapid Tests for non-prescription OTC, professional point-of-care and prescription use. These lateral flow, rapid antigen
Appointment of New CEO
19
diagnostic tests are designedCarrie Eglinton Manner was appointed President and Chief Executive Officer, effective June 4, 2022. Ms. Eglinton Manner also joined the OraSure Board of Directors (the "Board"). She succeeded Dr. Nancy Gagliano, who was appointed interim CEO in March 2022. Dr. Gagliano continues to detect active COVID-19 infection with a simple, easy-to-use workflow, using samples self-collected from the lower nostrils. After users swab their lower nostrils, the test stick is swirled in a pre-measured buffer solution. No instrumentation, batteries, smart phone or laboratory analysis is needed to read the result, which appearsserve on the test stick a short time later. During the third quarter of 2021 and for nine-month period ending September 30, 2021, we recorded $7.7 million of InteliSwabTM sales.
Following discussions with the FDA and their de-prioritization of antibody testing in the U.S., we decided to no longer pursue EUAs for a COVID-19 antibody enzyme-linked immunosorbent assay ("ELISA") for use in laboratory settings. We are, however, continuing to offer this product for research use only to labs and other parties interested in COVID antibody surveillance and research applications.
DLA Procurement Contract
In September 2021, we entered into a contract with the Defense Logistics Agency ("DLA") for the procurement of our InteliSwab™ COVID-19 Rapid Test for OTC use, which the DLA estimated to have a value of $205 million. Under the terms of the contract, the Company will provide its InteliSwab™ COVID-19 Rapid Test to up to 25,000 sites throughout the United States. The contract will run from October 2021 through September 2022.OraSure Board.
21
Ms. Eglinton Manner, age 48, has years of leadership experience across multiple disciplines. Prior to joining the Company, Ms. Eglinton Manner served as Senior Vice President, Advanced & General Diagnostic and Clinical Solutions at Quest Diagnostics since January 2017. Prior to Quest, Ms. Eglinton Manner spent over 20 years in various leadership roles in healthcare businesses at GE Healthcare. From 2009 through 2016, she served as President & CEO of four distinct GE Healthcare global businesses in the areas of diagnostic imaging, lab services and medical devices. She has served as a director of Repligen Corporation since June 2020. Ms. Eglinton Manner holds a B.S. in mechanical engineering from the University of Notre Dame.
BARDA 510(k) funding
Exploration of Strategic Alternatives
Ms. Eglinton Manner’s appointment as CEO came in tandem with a decision by the OraSure Board to conclude its previously announced review of strategic alternatives and for the Company to move forward under her leadership. Market conditions and the Board’s belief in the Company’s ability to further build upon recent operational successes with Ms. Eglinton Manner’s leadership were factors in the decision.
In September 2021, we entered into an agreement with the Biomedical Advanced Research Development Authority (“BARDA”), which is part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (“HHS”), pursuant to which BARDA will provide up to $13.6 million in funding for us to obtain 510(k) clearance and Clinical Laboratory Improvement Amendments (“CLIA”) waiver of our InteliSwab™ COVID-19 rapid test from the U.S. Food and Drug Administration (“FDA”).
DOD Manufacturing Capacity funding
In September 2021, we also entered into an agreement for $109 million in funding from the U.S. Department of Defense (the “DOD”), in coordination with the Department of Health and Human Services, to build additional manufacturing capacity in the United States for our InteliSwab™ COVID-19 rapid tests as part of the nation’s pandemic preparedness plan. Under this agreement, the funding will be used to expand our production capacity by 100 million tests annually. Funding will be paid to the Company based on achievement of milestones through March 2024 for the design, acquisition, installation, qualification and acceptance of the manufacturing equipment, as set forth in the agreement. An existing Company location in Bethlehem, PA will be retrofitted to accommodate increased manufacturing and an additional new facility will be added in another U.S. location to be determined.
Current Consolidated Financial Results
During the ninesix months ended SeptemberJune 30, 2021,2022, our consolidated net revenues increased 56%27% to $170.1$147.9 million, compared to $108.9$116.2 million for the ninesix months ended SeptemberJune 30, 2020.2021. Net product and services revenues during the ninesix months ended SeptemberJune 30, 20212022 increased 56%29% when compared to the same period of 2020,2021, largely due to increasedthe inclusion of $65.3 million of InteliSwab® COVID-19 rapid test revenues. We began selling this product in August of 2021 resulting in no comparable revenues across all products lines, other than our international HIV self-test. The biggest contributors toin the increased revenues for the period were higherfirst half of 2021. Declines in sales of our genomics products and our molecular sample collection kits for COVID-19 testing, lower laboratory services revenues, and the first time inclusion ofa decline in domestic sales of our InteliSwabTM COVID-19 rapid tests.HIV products partially offset this positive driver of revenue. Other revenues for the ninesix months ended SeptemberJune 30, 20212022 were $4.6$3.5 million compared to $2.9$3.9 million in the same period of 2020.2021. This increasedecrease was largely due to increased research and development funding for the development of our COVID-19 tests and higherlower royalty income.
Our consolidated net loss for the ninesix months ended SeptemberJune 30, 20212022 was $12.6$38.8 million, or $0.18$0.54 per share on a fully diluted basis, compared to a consolidated net lossincome of $16.8$2.4 million, or $0.25$0.03 per share on a fully diluted basis, for the ninesix months ended SeptemberJune 30, 2020.2021. Results for the ninesix months ended SeptemberJune 30, 2021 included a $1.5 million non-cash pre-tax benefit2022 were impacted by lower gross margins rates caused by an unfavorable product mix of higher sales of lower margin products, increases in inventory reserves associated with the changeexcess inventory levels and manufacturing inefficiencies that occurred in the fair valuefirst quarter of acquisition-related contingent consideration2022, lower absorption of labor costs and the absence of the Gates subsidy which accounted for approximately $0.02 per share. Results forexpired in June 2021. Also contributing to our net loss is an increase in operating expense as a result of impairment charges taken in the nine months ended September 30, 2020 included a $390,000 non-cash pre-tax chargesecond quarter of 2022 on idle manufacturing lines and goodwill, severance charges and accelerated stock compensation expense associated with the change in the fair valueour CEO transition and termination of acquisition-related contingent considerationour general counsel, and $393,000 of acquisition related transactionnonrecurring costs associated with the UrSure acquisition, which together accounted for approximately $0.01 per share.our strategic alternatives process.
Cash used in operating activities during the ninesix months ended SeptemberJune 30, 20212022 was $22.6$45.5 million. Cash provided byused in operating activities during the ninesix months ended SeptemberJune 30, 20202021 was $2.2$3.5 million. During the first half of 2022, our cash flow used in operating activities increased significantly as a result of our net loss and increased working capital requirements we scale our InteliSwab® manufacturing capacity to meet higher demand. As of SeptemberJune 30, 2021,2022, we had $202.3$95.8 million in cash, cash equivalents and available-for-sale securities, compared to $257.1 million at December 31, 2020.securities.
20
Results of Operations
Three months ended SeptemberJune 30, 20212022 compared to SeptemberJune 30, 20202021
CONSOLIDATED NET REVENUES
The table below shows a breakdown of total consolidated net revenues (dollars in thousands) generated by each of our business segments during the three months ended SeptemberJune 30, 20212022 and 2020.2021.
|
| Three Months Ended September 30, |
|
| |||||||||||||||||||
|
| Dollars |
|
|
|
|
|
| Percentage of Total Net Revenues |
|
| ||||||||||||
|
| 2021 |
|
| 2020 |
|
| % Change |
|
|
| 2021 |
|
|
| 2020 |
|
| |||||
Diagnostics |
| $ | 23,281 |
|
| $ | 15,540 |
|
|
| 50 |
| % |
|
| 43 |
| % |
|
| 32 |
| % |
Molecular Solutions |
|
| 29,948 |
|
|
| 31,209 |
|
|
| (4 | ) |
|
|
| 56 |
|
|
|
| 65 |
|
|
Net product and services revenues |
|
| 53,229 |
|
|
| 46,749 |
|
|
| 14 |
|
|
|
| 99 |
|
|
|
| 97 |
|
|
Other |
|
| 688 |
|
|
| 1,262 |
|
|
| (45 | ) |
|
|
| 1 |
|
|
|
| 3 |
|
|
Net revenues |
| $ | 53,917 |
|
| $ | 48,011 |
|
|
| 12 |
| % |
|
| 100 |
| % |
|
| 100 |
| % |
|
| For the Three Months Ended June 30, |
|
| |||||||||||||||||||
|
| Dollars |
|
|
|
|
|
| Percentage of Total Net Revenues |
|
| ||||||||||||
|
| 2022 |
|
| 2021 |
|
| % Change |
|
|
| 2022 |
|
|
| 2021 |
|
| |||||
Diagnostics |
| $ | 59,976 |
|
| $ | 18,252 |
|
|
| 229 |
| % |
|
| 75 |
| % |
|
| 32 |
| % |
Molecular Solutions |
|
| 19,191 |
|
|
| 37,489 |
|
|
| (49 | ) |
|
|
| 24 |
|
|
|
| 65 |
|
|
Net product and services revenues |
|
| 79,167 |
|
|
| 55,741 |
|
|
| 42 |
|
|
|
| 99 |
|
|
|
| 97 |
|
|
Other |
|
| 1,064 |
|
|
| 1,866 |
|
|
| (43 | ) |
|
|
| 1 |
|
|
|
| 3 |
|
|
Net revenues |
| $ | 80,231 |
|
| $ | 57,607 |
|
|
| 39 |
| % |
|
| 100 |
| % |
|
| 100 |
| % |
Consolidated net product and services revenues increased 14%42% to $53.2$79.2 million for the three months ended SeptemberJune 30, 20212022 from $46.7$55.7 million for the three months ended SeptemberJune 30, 2020.2021. The increase in revenues was is largely driven by increased genomic product sales anddue to the first time inclusion of sales$43.1 million of our InteliSwabTM® COVID-19 rapid teststest revenues. We began selling this product in August of 2021 resulting in no comparable revenues in the second quarter of 2021. Declines in,
22
revenues across all other product line partially offset by a decline in salesthis positive driver of ourmolecular sample collection kits for COVID-19 testing.revenue. Other revenues for the three months ended SeptemberJune 30, 20212022 decreased 45%43% to $688,000$1.1 million from $1.3$1.9 million for the three months ended SeptemberJune 30, 20202021 due to expected lower research and development funding forassociated with the development of our InteliSwab®COVID-19 testsrapid test and our HIV medication adherence testslower royalty income..
Consolidated net revenues derived from products sold to customers outside of the United States were $10.9$9.9 million and $9.4$10.0 million, or 20%12% and 17% of total net revenues, in each period, for the three months ended SeptemberJune 30, 20212022 and 2020,2021, respectively. Because the majority of our international sales are denominated in U.S. dollars, the impact of fluctuating foreign currency exchange rates was not material to our total consolidated net revenues.
Net Revenues by Segment
Diagnostics Segment
The table below shows a breakdown of total net revenues (dollars in thousands) generated by our Diagnostics segment during the three months ended SeptemberJune 30, 20212022 and 2020.2021.
|
| Three Months Ended September 30, |
|
|
| For the Three Months Ended June 30, |
|
| ||||||||||||||||||||||||||||||||||||||
|
| Dollars |
|
|
| Percentage of Total Net Revenues |
|
|
| Dollars |
|
|
|
| Percentage of Total Net Revenues |
|
| |||||||||||||||||||||||||||||
Market |
| 2021 |
| 2020 |
| % Change |
|
| 2021 |
|
| 2020 |
|
| 2022 |
|
| 2021 |
|
| % Change |
|
|
| 2022 |
|
| 2021 |
|
| ||||||||||||||||
Infectious disease testing |
| $ | 12,932 |
|
| $ | 13,224 |
|
|
| (2 | ) | % |
|
| 55 |
| % |
|
| 81 |
| % | |||||||||||||||||||||||
Infectious disease testing: |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||||||||||||||||||||||
COVID-19 |
|
| 7,675 |
|
|
| 63 |
|
| NM |
|
|
|
| 33 |
|
| NM |
|
|
| $ | 43,114 |
|
| $ | 89 |
|
| NM |
| % |
|
| 71 |
| % |
|
| 0 |
| % | ||||
Risk assessment testing |
|
| 2,674 |
|
|
| 2,253 |
|
|
| 19 |
|
|
|
| 11 |
|
|
|
| 14 |
|
| |||||||||||||||||||||||
Other |
|
| 14,232 |
|
|
| 15,534 |
|
|
| (8 | ) |
|
| 23 |
|
|
| 80 |
|
| |||||||||||||||||||||||||
Total infectious disease testing |
|
| 57,346 |
|
|
| 15,623 |
|
|
| 267 |
|
|
| 95 |
|
|
| 81 |
|
| |||||||||||||||||||||||||
Substance abuse testing |
|
| 2,630 |
|
|
| 2,629 |
|
|
| 0 |
|
|
|
| 4 |
|
|
|
| 14 |
|
| |||||||||||||||||||||||
Net product revenues |
|
| 23,281 |
|
|
| 15,540 |
|
|
| 50 |
|
|
|
| 99 |
|
|
|
| 95 |
|
|
|
| 59,976 |
|
|
| 18,252 |
|
|
| 229 |
|
|
|
| 99 |
|
|
|
| 95 |
|
|
Other |
|
| 230 |
|
|
| 774 |
|
|
| (70 | ) |
|
|
| 1 |
|
|
|
| 5 |
|
|
|
| 479 |
|
|
| 1,059 |
|
|
| (55 | ) |
|
|
| 1 |
|
|
|
| 5 |
|
|
Net revenues |
| $ | 23,511 |
|
| $ | 16,314 |
|
|
| 44 |
| % |
|
| 100 |
| % |
|
| 100 |
| % |
| $ | 60,455 |
|
| $ | 19,311 |
|
|
| 213 |
| % |
|
| 100 |
| % |
|
| 100 |
| % |
NM - not meaningful
Infectious Disease Testing Market
Sales to the infectious disease testing market decreased 2% to $12.9COVID-19 revenues were $43.1 million for the three months ended SeptemberJune 30, 2022, driven by sales of our InteliSwab® COVID-19 rapid test. We first began selling this product in August of 2021 from $13.2and there are no comparable sales in the second quarter of 2021.
Sales to the other infectious disease testing markets decreased 8% to $14.2 million for the three months ended SeptemberJune 30, 2020.2022 from $15.5 million for the three months ended June 30, 2021. This decrease resulted from lower world-wideworldwide OraQuick® HIV and international OraQuick® HCV product sales, partially offset by higher domestic OraQuick® HCV product sales.
21
The table below shows a breakdown of our total net OraQuick® HIV and HCV product revenues (dollars in thousands) during the three months ended SeptemberJune 30, 20212022 and 2020.2021.
|
| Three Months Ended September 30, |
|
| |||||||||
Market |
| 2021 |
|
| 2020 |
|
| % Change |
|
| |||
Domestic HIV |
| $ | 3,440 |
|
| $ | 3,909 |
|
|
| (12 | ) | % |
International HIV |
|
| 6,582 |
|
|
| 6,865 |
|
|
| (4 | ) |
|
Net HIV revenues |
|
| 10,022 |
|
|
| 10,774 |
|
|
| (7 | ) |
|
Domestic HCV |
|
| 1,827 |
|
|
| 1,186 |
|
|
| 54 |
|
|
International HCV |
|
| 888 |
|
|
| 1,033 |
|
|
| (14 | ) |
|
Net HCV revenues |
|
| 2,715 |
|
|
| 2,219 |
|
|
| 22 |
|
|
Net OraQuick® revenues |
| $ | 12,737 |
|
| $ | 12,993 |
|
|
| (2 | ) | % |
|
| For the Three Months Ended June 30, |
|
| |||||||||
Market |
| 2022 |
|
| 2021 |
|
| % Change |
|
| |||
Domestic HIV |
| $ | 3,741 |
|
| $ | 4,135 |
|
|
| (10 | ) | % |
International HIV |
|
| 6,616 |
|
|
| 6,809 |
|
|
| (3 | ) |
|
Net HIV revenues |
|
| 10,357 |
|
|
| 10,944 |
|
|
| (5 | ) |
|
Domestic HCV |
|
| 2,537 |
|
|
| 2,571 |
|
|
| (1 | ) |
|
International HCV |
|
| 1,154 |
|
|
| 1,729 |
|
|
| (33 | ) |
|
Net HCV revenues |
|
| 3,691 |
|
|
| 4,300 |
|
|
| (14 | ) |
|
Net OraQuick® revenues |
| $ | 14,048 |
|
| $ | 15,244 |
|
|
| (8 | ) | % |
Domestic OraQuick® HIV sales decreased 12%10% to $3.4$3.7 million for the three months ended SeptemberJune 30, 20212022 from $3.9$4.1 million for the three months ended SeptemberJune 30, 2020,2021, primarily as a result of a large second quarter 2021 order of our OraQuick® In-Home HIV test shipped to the timingCDC and used in an initiative to drive increased in-home HIV testing. A similar order did not occur in the second quarter of orders placed for our OraQuick® In-Home test.2022.
International sales of our OraQuick® HIV tests decreased 4%3% to $6.6 million for the three months ended SeptemberJune 30, 20212022 from $6.9$6.8 million for the three months ended SeptemberJune 30, 2020. This2021 due to the absence of the Gates Foundation subsidy which expired in June 2021 and is not included in revenues in the second quarter of 2022, initial stocking orders into Asia that did not recur in 2022, and the impact of the Russian and Ukraine war. These decline in revenues was primarily due to lower subsidies forwere partially offset by increased sales into Africa as the international sale of our HIV Self-Test under the charitable support agreement with the Gates Foundation. The Gates agreement and subsidy provided thereunder expired on June 30, 2021.COVID-19 impact lessens.
23
Domestic OraQuick® HCV sales increased 54% to $1.8remained largely flat at $2.5 million for the three months ended SeptemberJune 30, 2021 from $1.22022 compared to $2.6 million for the three months ended SeptemberJune 30, 2020, due to the re-opening of testing programs previously closed as a result of the COVID-19 pandemic and as resources used for COVID-19 testing and vaccinations were redirected back to HCV testing.2021.
International OraQuick® HCV sales decreased 14%33 % to $888,000 for the three months ended September 30, 2021 from $1.0$1.2 million for the three months ended SeptemberJune 30, 2020 due2022 compared to customer ordering patterns.
COVID-19 Testing Market
During$1.7 million for the three months ended SeptemberJune 30, 2021 COVID-19 revenues were $7.7 million, driven by the first time sales of our InteliSwabTM COVID-19 rapid testdue to a stock order into Korea which were limited by manufacturing constraintsdid no repeat in the quarter.2022.
Risk AssessmentSubstance Abuse Testing Market
Sales to the risksubstance abuse testing assessment market increased 19% to $2.7remained flat at $2.6 million for both the three months ended SeptemberJune 30, 2021 compared to $2.3 million for the three months ended September 30, 2020 due to hiring increases driven by the economic recovery from the COVID-19 pandemic.2022 and 2021.
Other Revenues
Other revenues for the three months ended SeptemberJune 30, 20212022 decreased 55% to $230,000$479,000 from $774,000$1.1 million for the three months ended SeptemberJune 30, 2020,2021, due to lower research and development funding associated with our InteliSwabfunding for the development of our® COVID-19 tests and our HIV medication adherence testsrapid test..
Molecular Solutions Segment
The table below shows a breakdown of our total net revenues (dollars in thousands) during the three months ended SeptemberJune 30, 20212022 and 2020.2021.
|
| Three Months Ended September 30, |
|
|
| For the Three Months Ended June 30, |
|
| ||||||||||||||||||
Market | Market | 2021 |
| 2020 |
| % Change |
| Market | 2022 |
|
| 2021 |
|
| % Change |
|
| |||||||||
Genomics |
| $ | 19,018 |
|
| $ | 8,454 |
|
|
| 125 |
| % |
| $ | 15,486 |
|
| $ | 19,498 |
|
|
| (21 | ) | % |
Microbiome |
|
| 1,693 |
|
|
| 1,530 |
|
|
| 11 |
|
|
|
| 1,832 |
|
|
| 2,447 |
|
|
| (25 | ) |
|
COVID-19 |
|
| 6,255 |
|
|
| 18,804 |
|
|
| (67 | ) |
|
|
| 264 |
|
|
| 11,981 |
|
|
| (98 | ) |
|
Laboratory services |
|
| 2,406 |
|
|
| 2,280 |
|
|
| 6 |
|
|
|
| 1,204 |
|
|
| 3,114 |
|
|
| (61 | ) |
|
Other product and service revenues |
|
| 576 |
|
|
| 141 |
|
|
| 309 |
|
|
|
| 405 |
|
|
| 449 |
|
|
| (10 | ) |
|
Net molecular product and services revenues |
| $ | 29,948 |
|
| $ | 31,209 |
|
|
| (4 | ) |
|
| $ | 19,191 |
|
|
| 37,489 |
|
|
| (49 | ) |
|
Other |
|
| 458 |
|
|
| 488 |
|
|
| (6 | ) |
|
|
| 585 |
|
|
| 807 |
|
|
| (28 | ) |
|
Net molecular product and services revenues |
| $ | 30,406 |
|
| $ | 31,697 |
|
|
| (4 | ) | % | |||||||||||||
Net molecular revenues |
| $ | 19,776 |
|
| $ | 38,296 |
|
|
| (48 | ) | % |
22
Sales of our genomics products increased 125%decreased 21% to $19.0$15.5 million for the three months ended SeptemberJune 30, 20212022, compared to $8.5$19.5 million for the three months ended SeptemberJune 30, 2020,2021, as this product line experienced a strong rebound from the impactresult of the COVID-19 pandemic in the prior period and benefited fromcustomer ordering patterns of our larger customers.patterns.
Microbiome kit sales increased 11%decreased 25% to $1.7$1.8 million for the three months ended SeptemberJune 30, 20212022 compared to $1.5$2.4 million for the three months ended SeptemberJune 30, 2020,2021, due to customer ordering patterns.lower sales to certain Clinical Research Organizations ("CROs") as a result of delays in microbiome clinical studies.
Sales of our molecular sample collection kits for COVID-19 testing decreased 67%98% to $6.3$264,000 for the three months ended June 30, 2022 compared to $12.0 million during the comparable period in 2021 due to lower COVID-19 PCR testing sales to our core customers, driven by the availability of antigen tests, the wider availability of vaccines and high inventory levels held by some of those customers and the termination of public funding for PCR testing.
Laboratory services revenues declined 61% to $1.2 million for the three months ended SeptemberJune 30, 20212022 compared to $18.8 million during the comparable period in 2020 due to lower COVID-19 PCR testing demand and the impact of the wider availability of vaccines.
Laboratory services revenues increased 6% to $2.4$3.1 million for the three months ended SeptemberJune 30, 2021 compared to $2.3 million for the three months ended September 30, 2020 as a result of a large customer ceasing its operations and due to customers resuming activities delayed by the COVID-19 pandemic.timing of clinical trials.
Other product and service revenues increased 309% to $576,000 forremained largely unchanged at $405,000 in the three months ended September 30, 2021second quarter of 2022 compared to $141,000 for$449,000 in the three months ended September 30, 2020 due to increased salessecond quarter of our Colli-Pee® collection device.2021.
Other revenues for the three months ended SeptemberJune 30, 20212022 decreased 6%28% to $458,000$585,000 from $488,000$807,000 for the three months ended SeptemberJune 30, 2020,2021, largely as a result of lower royalty income received under a litigation settlement agreement.
CONSOLIDATED OPERATING RESULTS
Consolidated gross profit percentage was 40%margins were 34% for the three months ended SeptemberJune 30, 20212022 compared to 63%53% for the three months ended SeptemberJune 30, 2020. 2021. The decrease in gross profit percentagemargins was primarily due to a less favorable product mix and increased scrap expense lower absorption of labor, and associated with reserves for excess inventory.lower subsidies for the international sale of our HIV Self-Test under the charitable support agreement with the Gates Foundation.
Consolidated operating loss for the three months ended SeptemberJune 30, 20212022 was $13.0$21.3 million, a $17.4$23.1 million decrease from the $4.4$1.8 million operating income reported for the three months ended SeptemberJune 30, 2020.2021. Results for the three months ended SeptemberJune 30, 20212022 were negatively impacted by the
24
lower gross profit percentage andmargin described above coupled with an increase in operating expenses.expenses as described below, including an aggregate impairment charge of $10.5 million.
OPERATING INCOME (LOSS) BY SEGMENT
We evaluate performance of our operating segments based on revenue and operating income. Reportable segments have no inter-segment revenue and inter-segment expenses are eliminated in consolidation, including the fees associated with an intercompany service agreement between Diagnosticsthe U.S. and Molecular Solutions.Canadian entities.
Diagnostics Segment
The gross profit percentagemargin for the Diagnostics segment was 16%36% for the three months ended SeptemberJune 30, 20212022 compared to 44%34% for the three months ended SeptemberJune 30, 2020.2021. This decreaseincrease is due to an increase in scrap costs associated with the production of our InteliSwabTM test, and the recording of a reserve for COVID-19 antibody inventory, lower absorption of labor costs as we have increased headcount in anticipationimproved product mix of higher production demands, and lowermargin product sales partially offset by the June 2021 expiration of subsidies for the international sale of our HIV Self-Test under the charitable support agreement with the Gates FoundationFoundation..
Research and development expenses increased 3%26% to $5.9$6.3 million for the three months ended SeptemberJune 30, 20212022 compared to $5.7$5.0 million for the three months ended SeptemberJune 30, 20202021 largely due to higherincreased staffing costs associated with higher head count, increased clinical study activities related to obtaining CE mark for our InteliSwab® rapid test and higher subscription costs associated with our new quality system. Sales and marketing expenses increased 19% to $7.8 million for three months ended June 30, 2022 from $6.6 million for the three months ended June 30, 2021 due to increased staffing costs associated with higher head count and increased travel, trade show, and annual meetings expenses as travel and in person events have resumed as COVID-19 restrictions have been lifted. These increases in spend to investigate InteliSwabTM manufacturing issues,were partially offset by a decline in COVID-19 lab supplyadvertising and market research costs associated with reduced product development activities from the prior year period. Salesour InteliSwab® test. General and marketingadministrative expenses increased 83%54% to $9.0 million for three months ended September 30, 2021 from $4.9$11.0 million for the three months ended SeptemberJune 30, 2020 due to an increase in advertising spend associated with the introduction of our InteliSwabTM test into the market, higher commissions associated with the revenue increase, and increased consulting expense associated with business strategy planning. General and administrative expenses increased 24% to $8.02022 from $7.1 million for the three months ended SeptemberJune 30, 2021 from $6.5 million for the three months ended September 30, 2020 largely due to increased business development consulting spend, increased staffingseverance costs and accelerated stock compensation expense associated with our former general counsel's employment and termination agreements, stock compensation costs associated with increased headcountrestricted stock awards granted to certain board members with immediate vesting provisions, and higher recruiting expenses. We are anticipating higherlegal, accounting, and information technologies contract fees.
Operating expenses for the Diagnostic segment also include an impairment charge of $4.9 million associated with an idle manufacturing line for which it has no projected cash flow and minimal resale or salvage value. Diagnostic operating expenses also included a goodwill impairment charge of $3.6 million. The decline in the fourth quarterCompany's stock price was identified as a triggering event which required the Company to perform an quantitative goodwill impairment analysis. The results of 2021 as several of our on-going InteliSwabTM post marketing clinical studies will leadthis analysis indicated the Diagnostic segment's goodwill was impaired and was written down to higher research and development expenses. In addition, we expect higher sales and marketing and general and administrative costs as we prepare for significant commercial ramp up of our InteliSwabTM business in 2022.$0.
All of the above contributed to the Diagnostics segment’s operating loss of $18.6$11.8 million for the three months ended SeptemberJune 30, 2021,2022, which included the non-cash impairment charges of $8.5 million, non-cash charges of $1.1$1.9 million for depreciation and amortization and $1.9$2.8 million for stock-based compensation. The Diagnostics
23
segment operating loss alsoin the second quarter of 2021 included a $220,000 non-cash pre-tax benefit of $500,000 associated with the change in the fair value of acquisition-related contingent consideration. There was no similar benefit recorded in the second quarter of 2022.
Molecular Solutions Segment
The gross profit percentagemargin for the Molecular Solutions segment was 58%31% for the three months ended SeptemberJune 30, 20212022 compared to 73%63% for the three months ended SeptemberJune 30, 2020.2021. This decrease was due to an increase in reserves for excess inventory as result of a forecasted decline in demand of certain products used in COVID PCR testing and a less favorable product mix associated with the higher sales of lower gross profit percentage product and an increase in costs at our third party contract manufacturers resulting from the capacity expansion at those vendors.mix.
Research and development expenses increased 17% toremained relatively flat at $2.8 for the three months ended June 30, 2022 from $2.7 million for the three months ended SeptemberJune 30, 2021 from $2.3. Sales and marketing expenses also remained flat at $3.9 million for the three months ended SeptemberJune 30, 2020 due to higher staffing costs. Sales2022 and marketing2021. General and administrative expenses increased 67%70% to $4.9$6.6 million for the three months ended SeptemberJune 30, 20212022 from $2.9$3.9 million for the three months ended SeptemberJune 30, 20202021 due to increased consulting expense associated with business strategy planning,legal fees.
Operating expenses for the Molecular segment also include an increase in our reserve for uncollectible accounts, and higher staffing costs. General and administrative expenses increased 23% to $4.4impairment charge of $2.0 million for the three months ended SeptemberJune 30, 2021 from $3.6 million2022 associated with two idle manufacturing lines for the three months ended September 30, 2020 due to increased legal feeswhich there are no projected cash flow and staffing costs.minimal resale or salvage value.
All of the above contributed to the Molecular Solutions segment’s operating incomeloss of $5.6$9.5 million for the three months ended SeptemberJune 30, 2021,2022, which included $2.2the non-cash impairment charge of $2.0 million, non-cash charges of $1.9 million for depreciation and amortization and $301,000$529,000 for stock-based compensation.
CONSOLIDATED INCOME TAXES
25
We continue to believe the full valuation allowance established against our total U.S. deferred tax asset is appropriate as the facts and circumstances necessitating the allowance have not changed. For the three months ended SeptemberJune 30, 2021,2022, we recorded a U.S. state tax benefitexpense of $102,000$183,000 compared to a $629,000$54,000 of state income tax benefit for the three months ended SeptemberJune 30, 2020.2021. For the three months ended SeptemberJune 30, 2021,2022, we recorded a foreign tax expensebenefit of $2.2$1.3 million compared to foreign tax expense of $4.3$3.7 million for the three months ended SeptemberJune 30, 2020. The2021. This overall decrease in foreign tax expense is largely a result of the decrease in income before taxes generated by our Canadian subsidiary.
Nine
Six months ended SeptemberJune 30, 20212022 compared to SeptemberJune 30, 2020
2021
CONSOLIDATED NET REVENUES
The table below shows a breakdown of total consolidated net revenues (dollars in thousands) generated by each of our business segments forduring the ninesix months ended SeptemberJune 30, 20212022 and 2020.2021.
|
| Nine Months Ended September 30, |
|
|
| For the Six Months Ended June 30, | ||||||||||||||||||||||||||||||||||||||
|
| Dollars |
|
|
| Percentage of Total Net Revenues |
|
|
| Dollars |
|
|
|
| Percentage of Total Net Revenues |
|
| |||||||||||||||||||||||||||
|
| 2021 |
| 2020 |
| % Change |
|
| 2021 |
|
| 2020 |
|
| 2022 |
|
| 2021 |
|
| % Change |
|
| 2022 |
|
| 2021 |
|
| |||||||||||||||
Diagnostics |
| $ | 54,867 |
|
| $ | 43,473 |
|
|
| 26 |
| % |
| 32 |
| % |
| 40 |
| % |
| $ | 96,372 |
|
| $ | 31,585 |
|
|
| 205 |
| % |
| 65 |
| % |
|
| 27 |
| % | |
Molecular Solutions |
|
| 110,682 |
|
|
| 62,499 |
|
|
| 77 |
|
|
| 65 |
|
|
|
| 57 |
|
|
|
| 48,031 |
|
|
| 80,735 |
|
|
| (41 | ) |
|
| 33 |
|
|
| 69 |
|
| |
Net product and services revenues |
|
| 165,549 |
|
|
| 105,972 |
|
|
| 56 |
|
|
| 97 |
|
|
| 97 |
|
|
|
| 144,403 |
|
|
| 112,320 |
|
|
| 29 |
|
|
| 98 |
|
|
| 96 |
|
| ||
Other |
|
| 4,557 |
|
|
| 2,894 |
|
|
| 57 |
|
|
| 3 |
|
|
|
| 3 |
|
|
|
| 3,535 |
|
|
| 3,869 |
|
|
| (9 | ) |
|
| 2 |
|
|
| 4 |
|
| |
Net revenues |
| $ | 170,106 |
|
| $ | 108,866 |
|
|
| 56 |
| % |
| 100 |
| % |
|
| 100 |
| % |
| $ | 147,938 |
|
| $ | 116,189 |
|
|
| 27 |
| % |
| 100 |
| % |
|
| 100 |
| % |
Consolidated net product and services revenues increased 56%29% to $165.5$144.4 million for the ninesix months ended SeptemberJune 30, 20212022 from $106.0$112.3 million for the comparable period of 2020, six months ended June 30, 2021. The increase in revenues is largely due to increasedthe inclusion of $65.3 million of InteliSwab® COVID-19 rapid test revenues. We began selling this product in August of 2021 resulting in no comparable revenues across all products lines, other than our international HIV self-test. The biggest contributors toin the increased revenues for the period were higherfirst half of 2021. Declines in sales of our genomics products and our molecular sample collection kits for COVID-19 testing and the first time inclusionpartially offset this positive driver of sales of our InteliSwabTM COVID-19 rapid tests.revenue. Other revenues for the ninesix months ended SeptemberJune 30, 2021 increased 57%2022 decreased 9% to $4.6$3.5 million from $2.9$3.9 million for the ninesix months ended SeptemberJune 30, 2020. This increase was2021 largely due to increased research and development funding for the development of our COVID-19 tests and higherlower royalty income.
Consolidated net revenues derived from products sold to customers outside of the United States were $30.4$19.6 million and $26.7$19.5 million, or 18%13% and 25%17% of total net revenues, infor the first ninesix months ofended June 30, 2022 and 2021, and 2020, respectively. Because the majority of our international sales are denominated in U.S. dollars, the impact of fluctuating foreign currency exchange rates was not material to our total consolidated net revenues.
Net Revenues by Segment
Diagnostics Segment
24
The table below shows a breakdown of total net revenues (dollars in thousands) generated by our Diagnostics segment during the ninesix months ended SeptemberJune 30, 20212022 and 2020.2021.
|
| Nine Months Ended September 30, |
|
| |||||||||||||||||||
|
| Dollars |
|
|
|
|
|
| Percentage of Total Net Revenues |
|
| ||||||||||||
Market |
| 2021 |
|
| 2020 |
|
| % Change |
|
|
| 2021 |
|
|
| 2020 |
|
| |||||
Infectious disease testing |
| $ | 39,664 |
|
| $ | 36,625 |
|
|
| 8 |
| % |
|
| 69 |
| % |
|
| 82 |
| % |
COVID-19 |
|
| 7,938 |
|
|
| 63 |
|
| NM |
|
|
|
| 14 |
|
|
| NM |
|
| ||
Risk assessment testing |
|
| 7,265 |
|
|
| 6,786 |
|
|
| 7 |
|
|
|
| 13 |
|
|
|
| 15 |
|
|
Net product revenues |
|
| 54,867 |
|
|
| 43,474 |
|
|
| 26 |
|
|
|
| 96 |
|
|
|
| 97 |
|
|
Other |
|
| 2,501 |
|
|
| 1,060 |
|
|
| 136 |
|
|
|
| 4 |
|
|
|
| 3 |
|
|
Net revenues |
| $ | 57,368 |
|
| $ | 44,534 |
|
|
| 29 |
| % |
|
| 100 |
| % |
|
| 100 |
| % |
|
| For the Six Months Ended June 30, |
|
| |||||||||||||||||||
|
| Dollars |
|
|
|
|
|
| Percentage of Total Net Revenues |
|
| ||||||||||||
Market |
| 2022 |
|
| 2021 |
|
| % Change |
|
|
| 2021 |
|
|
| 2020 |
|
| |||||
Infectious disease testing: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||
COVID-19 |
| $ | 65,250 |
|
| $ | 262 |
|
| NM |
| % |
|
| 66 |
| % |
|
| 0 |
| % | |
Other |
|
| 25,931 |
|
|
| 26,732 |
|
|
| (3 | ) |
|
|
| 25 |
|
|
|
| 79 |
|
|
Total infectious disease testing |
|
| 91,181 |
|
|
| 26,994 |
|
|
| 238 |
|
|
|
| 92 |
|
|
|
| 80 |
|
|
Substance abuse testing |
|
| 5,191 |
|
|
| 4,591 |
|
|
| 13 |
|
|
|
| 5 |
|
|
|
| 14 |
|
|
Net product revenues |
|
| 96,372 |
|
|
| 31,585 |
|
|
| 205 |
|
|
|
| 97 |
|
|
|
| 94 |
|
|
Other |
|
| 2,393 |
|
|
| 2,272 |
|
|
| 5 |
|
|
|
| 3 |
|
|
|
| 6 |
|
|
Net revenues |
| $ | 98,765 |
|
| $ | 33,857 |
|
|
| 192 |
| % |
|
| 100 |
| % |
|
| 100 |
| % |
NM - not meaningful
Infectious Disease Testing Market
COVID-19 revenues were $65.3 million for the six months ended June 30, 2022, driven by sales of our InteliSwab® COVID-19 rapid test. We first began selling this product in August of 2021 and there are no comparable sales in the first half of 2021.
26
Sales to the other infectious disease testing market increased 8%markets decreased 3% to $39.7$25.9 million for the ninesix months ended SeptemberJune 30, 20212022 from $36.6$26.7 million for the ninesix months ended SeptemberJune 30, 2020.2021. This increasedecrease resulted from lower domestic OraQuick® HIV and international OraQuick® HCV product sales, partially offset by higher domestic sales of ourinternational OraQuick® HIV and HCV products and higher international domestic OraQuick® HVC product sales, partially offset by lower sales of our international OraQuick® HIV Self-Tests.HCV sales.
The table below shows a breakdown of our total net OraQuick® HIV and HCV product revenues (dollars in thousands) during the ninesix months ended SeptemberJune 30, 20212022 and 2020.2021.
|
| Nine Months Ended September 30, |
|
| |||||||||
Market |
| 2021 |
|
| 2020 |
|
| % Change |
|
| |||
Domestic HIV |
| $ | 12,490 |
|
| $ | 11,323 |
|
|
| 10 |
| % |
International HIV |
|
| 17,255 |
|
|
| 17,697 |
|
|
| (2 | ) |
|
Net HIV revenues |
|
| 29,745 |
|
|
| 29,020 |
|
|
| 2 |
|
|
Domestic HCV |
|
| 5,580 |
|
|
| 3,437 |
|
|
| 62 |
|
|
International HCV |
|
| 3,802 |
|
|
| 2,772 |
|
|
| 37 |
|
|
Net HCV revenues |
|
| 9,382 |
|
|
| 6,209 |
|
|
| 51 |
|
|
Net OraQuick® revenues |
| $ | 39,127 |
|
| $ | 35,229 |
|
|
| 11 |
| % |
|
| Six Months Ended June 30, |
|
| |||||||||
Market |
| 2022 |
|
| 2021 |
|
| % Change |
|
| |||
Domestic HIV |
| $ | 7,506 |
|
| $ | 9,050 |
|
|
| (17 | ) | % |
International HIV |
|
| 11,017 |
|
|
| 10,672 |
|
|
| 3 |
|
|
Net HIV revenues |
|
| 18,523 |
|
|
| 19,722 |
|
|
| (6 | ) |
|
Domestic HCV |
|
| 4,574 |
|
|
| 3,754 |
|
|
| 22 |
|
|
International HCV |
|
| 2,374 |
|
|
| 2,914 |
|
|
| (19 | ) |
|
Net HCV revenues |
|
| 6,948 |
|
|
| 6,668 |
|
|
| 4 |
|
|
Net OraQuick® revenues |
| $ | 25,471 |
|
| $ | 26,390 |
|
|
| (3 | ) | % |
Domestic OraQuick® HIV sales increased 10%decreased 17% to $12.5$7.5 million for the ninesix months ended SeptemberJune 30, 20212022 from $11.3$9.1 million for the ninesix months ended SeptemberJune 30, 2020. This increase was2021, primarily theas a result of higher salesa large order fulfilled in the first half of 2021 for our OraQuick®OraQuick® In-Home HIV test shipped to the CDC and used in a Centers for Disease Control and Prevention ("CDC")an initiative to drive increased in-home HIV testing.
testing. A similar order did not occur in the first half of 2022.
International sales of our OraQuick® HIV tests decreased 2%increased 3% to $17.3$11.0 million for the ninesix months ended SeptemberJune 30, 20212022 from $17.7$10.7 million for the ninesix months ended SeptemberJune 30, 2020 largely2021 due to pricing associated withincreased sales into Africa as the expirationCOVID-19 impact lessens. This increase to revenues was partially offset by the absence of the Gates Foundation subsidy, for certain international tests.
which expired in June 2021 and is not included in revenues in the first quarter of 2022, as well as the impact of the Russia and Ukraine war.
Domestic OraQuick® HCV sales increased 62%22% to $5.6$4.6 million for the ninesix months ended SeptemberJune 30, 20212022 from $3.4$3.8 million for the ninesix months ended SeptemberJune 30, 2020 due to the re-opening of testing programs previously closed as a result of the COVID-19 pandemic and as resources used for COVID-192021, driven by new funding granted by certain state governments, increased legislation regarding drug testing and vaccinations were redirected back to HCVrise in drug use requiring more testing.
International OraQuick® HCV sales increased 37%decreased 19% to $3.8$2.4 million for the ninesix months ended SeptemberJune 30, 20212022 from $2.8$2.9 million for the ninesix months ended September 30, 2020 as sales into certain international markets continued to return to pre-pandemic levels.
COVID-19 Testing Market
During the nine months ended SeptemberJune 30, 2021 COVID-19 revenues were $7.9 million, driven by the first time sales of our InteliSwabTM COVID-19 rapid antigen test which begandue to large stock ordering shipped to Korea that did not repeat in the third quarter of 2021.
Risk Assessment Market
2022.
Sales to the risksubstance abuse testing assessment market increased 7%13% to $7.3$5.2 million for the ninesix months ended SeptemberJune 30, 20212022 compared to $6.8$4.6 million for the ninesix months ended SeptemberJune 30, 20202021 due to hiring increases driven by the economic recovery from the COVID-19 pandemic.market share gains.
25
Other Revenues
Other revenues for the ninesix months ended SeptemberJune 30, 20212022 increased minimally to $2.5$2.4 million from $1.1$2.3 million for the ninesix months ended SeptemberJune 30, 2020, largely2021, due higherto research and development funding for 510(k) clearance and CLIA waiver of our InteliSwab®COVID-19 tests and the inclusion ofrapid test partially offset by lower royalty income under the terms of a new licensing agreement related to our proprietary buffer solution used for the preservation and stabilization of oral fluid specimens.income.
Molecular Solutions Segment
The table below shows a breakdown of our total net revenues (dollars in thousands) during the ninesix months ended SeptemberJune 30, 20212022 and 2020.2021.
|
| Six Months Ended June 30, |
|
| |||||||||
Market | 2022 |
|
| 2021 |
|
| % Change |
|
| ||||
Genomics |
| $ | 30,578 |
|
| $ | 30,316 |
|
|
| 1 |
| % |
Microbiome |
|
| 3,822 |
|
|
| 4,198 |
|
|
| (9 | ) |
|
COVID-19 |
|
| 9,161 |
|
|
| 39,953 |
|
|
| (77 | ) |
|
Laboratory services |
|
| 2,938 |
|
|
| 5,611 |
|
|
| (48 | ) |
|
Other product revenues |
|
| 1,532 |
|
|
| 657 |
|
|
| 133 |
|
|
Net molecular product and services revenues |
| $ | 48,031 |
|
| $ | 80,735 |
|
|
| (41 | ) |
|
Other |
|
| 1,142 |
|
|
| 1,597 |
|
|
| (28 | ) |
|
Net molecular product and services revenues |
| $ | 49,173 |
|
| $ | 82,332 |
|
|
| (40 | ) | % |
27
|
| Nine Months Ended September 30, |
|
| |||||||||
Market | 2021 |
|
| 2020 |
|
| % Change |
|
| ||||
Genomics |
| $ | 49,333 |
|
| $ | 23,224 |
|
|
| 112 |
| % |
Microbiome |
|
| 5,888 |
|
|
| 3,869 |
|
|
| 52 |
|
|
COVID-19 |
|
| 46,209 |
|
|
| 27,855 |
|
|
| 66 |
|
|
Laboratory services |
|
| 8,017 |
|
|
| 6,798 |
|
|
| 18 |
|
|
Other product revenues |
|
| 1,235 |
|
|
| 752 |
|
|
| 64 |
|
|
Net molecular product and services revenues |
| $ | 110,682 |
|
| $ | 62,498 |
|
|
| 77 |
|
|
Other |
|
| 2,056 |
|
|
| 1,834 |
|
|
| 12 |
|
|
Net molecular product and services revenues |
| $ | 112,738 |
|
| $ | 64,332 |
|
|
| 75 |
| % |
Sales of our genomics products remained largely flat and increased 112%only 1% to $49.3$30.6 million for the ninesix months ended SeptemberJune 30, 20212022, compared to $23.2$30.3 million for the ninesix months ended SeptemberJune 30, 2020 as we continued to see our customers' businesses recover from the COVID-19 pandemic and strong organic growth from customers in the commercial animal markets.2021.
Microbiome kit sales increased 52%decreased 9% to $5.9$3.8 million for the ninesix months ended SeptemberJune 30, 20212022 compared to $3.9$4.2 million for the ninesix months ended SeptemberJune 30, 20202021, due to a recoverydecline in revenues to CROs driven by the market from the COVID-19 pandemic.timing of microbiome clinical studies.
Sales of our molecular sample collection kits for COVID-19 testing increased 66%decreased 77% to $46.2$9.2 million for the ninesix months ended SeptemberJune 30, 20212022 compared to $27.9$40.0 million during the comparable period in 20202021 due to increased demand aslower COVID-19 PCR testing sales to our core customers, driven by the COVID-19 pandemic began late inavailability of antigen tests, the first quarterwider availability of 2020vaccines, lower public funding for PCR testing, and testing ramped up in the second and third quartershigh inventory levels held by some of 2020 and continued into the first half of 2021 contributing to the revenue growth for the nine month period.those customers.
Laboratory services revenues increased 18%declined 48% to $8.0$2.9 million for the ninesix months ended SeptemberJune 30, 20212022 compared to $6.8$5.6 million for the ninesix months ended SeptemberJune 30, 2020, due to customers resuming activities delayed by the COVID-19 pandemic.2021 as a result of a large customer ceasing its operations and a slowdown in clinical trials.
Other product and service revenues increased 64%133% to $1.2$1.5 million for the ninesix months ended SeptemberJune 30, 2022 compared to $657,000 for the six months ended June 30, 2021 compared to $752,000 for the nine months ended September 30, 2020largely due to increased sales ofby our Colli-Pee® collection device.Novosanis subsidiary.
Other revenues for the ninesix months ended SeptemberJune 30, 2021 increased 12%2022 decreased 28% to $2.1$1.1 million from $1.8$1.6 million for the ninesix months ended SeptemberJune 30, 20202021, largely as a result of higherlower royalty income received under a litigation settlement agreement.
CONSOLIDATED OPERATING RESULTS
Consolidated gross profit percentage was 53%margins were 35% for the ninesix months ended SeptemberJune 30, 20212022 compared to 59% for the ninesix months ended SeptemberJune 30, 2020. Gross2021. The decrease in gross profit percentage formargins was caused by an unfavorable product mix of higher sales of lower margin product, increases in inventory reserves associated with excess inventory levels and manufacturing inefficiencies that occurred in the nine months ended September 30, 2021 declined as a resultfirst quarter of increased scrap expense,2022, lower absorption of labor costs and lower subsidies under the charitable support agreement withabsence of the Gates Foundation, partially offset by an improved product mix associated with an increasesubsidy which expired in higher gross profit percentage product sales.June 2021.
Consolidated operating loss for the ninesix months ended SeptemberJune 30, 20212022 was $793,000$37.3 million, a $12.3$49.5 million improvementdecrease from the $13.1$12.2 million operating lossincome reported for the ninesix months ended SeptemberJune 30, 2020.2021. Results for the ninesix months ended SeptemberJune 30, 20212022 were positively
26
negatively impacted by the increased revenues and the inclusion of an $1.5 million non-cash benefit relatedto the fair value change in acquisition-related contingent consideration partially offset by the lower gross profit percentage and increasedmargin described above coupled with an increase in operating expenses.expenses as described below, including an aggregate impairment charge of $10.5 million.
OPERATING INCOME (LOSS) BY SEGMENT
We evaluate performance of our operating segments based on revenue and operating income. Reportable segments have no inter-segment revenue and inter-segment expenses are eliminated in consolidation, including the fees associated with an intercompany service agreement between Diagnosticsthe U.S. and Molecular Solutions.Canadian entities.
Diagnostics Segment
The gross profit percentagemargin for the Diagnostics segment was 29% for the ninesix months ended SeptemberJune 30, 20212022 compared to 43%38% for the ninesix months ended SeptemberJune 30, 2020.2021. This decrease wasis due to an increaseinefficiencies in scrap costs associated with the production of our InteliSwabTM ®test and manufacturing process experienced in the recordingbeginning of a reserve for COVID-19 antibody inventory, and lower absorptionthe year causing high scrap rates, under-absorption of labor costs, as we have increased headcount in anticipationand the June 2021 expiration of higher production demandssubsidies under the support agreement with the Gates Foundation, and a less favorable product mix..
Research and development expenses increased 29%2% to $17.4$11.8 million for the ninesix months ended SeptemberJune 30, 2021 from $13.52022 compared to $11.5 million for the ninesix months ended September 30, 2020, largely due to higher staffing costs and increased COVID-19 product development expenses. Sales and marketing expenses increased 35% to $21.7 million for the nine months ended SeptemberJune 30, 2021 from $16.1 million for the nine months ended September 30, 2020, due to higher market research and advertising spending associated with the introduction of our InteliSwabTM test into the market, higher commissions directly related to the increase in revenues and increased consulting costs associated with business strategy planning. General and administrative expenses increased 4% to $21.6 million for the nine months ended September 30, 2021 from $20.7 million for the nine months ended September 30, 2020largely due to higher staffing costs associated with increased headcount,head count offset by lower product development activities related to our InteliSwab® rapid test which did not repeat in the first half of 2022 as we received EUA authorization in June 2021. Sales and marketing expenses increased 25% to $15.9 million for six months ended June 30, 2022 from $12.8 million for the six months ended June 30, 2021 due to increased staffing costs associated with higher head count, increased travel and annual meetings expenses as travel and in person events have resumed as COVID-19 restrictions have been lifted, increased consultant costs, higher advertising and market research expenses and higher business development consultingsubscription costs associated with our new CRM system. This increase in spending was partially offset by a decline in our reserve for uncollectible accounts, lower recruiting fees and a decrease in commission expense. General and administrative expenses increased 82% to $24.7 million for the six months ended June 30, 2022 from $13.6 million for the six months ended June 30, 2021 largely due to increased consulting costs, higher stock compensation expense associated with accelerated vesting of shares under our former CEO's and general counsel's employment agreements, higher staffing costs associated with increased head count, increased legal costs, severance costs associated with our former general counsel, increased accounting fees, and higher recruitment expense largely associated with our CEO search.
28
Operating expenses for the Diagnostic segment also include an impairment charge of $4.9 million associated with an idle manufacturing line for which it has no projected cash flow and minimal resale or salvage value. Diagnostic operating expenses also included a lower allocationgoodwill impairment charge of building costs$3.6 million. The decline in the Company's stock price was identified as administrative spacea triggering event which required the Company to perform an quantitative goodwill impairment analysis. The results of this analysis indicated the Diagnostic segment's goodwill was repurposed for manufacturing,impaired and increased intercompany service fees allocatedwas written down to the Molecular Solutions segment.$0.
All of the above contributed to the Diagnostics segment’s operating loss of $42.8$31.6 million for the ninesix months ended SeptemberJune 30, 2021,2022, which included the non-cash impairment charge of $8.5 million, non-cash charges of $3.0$3.6 million for depreciation and amortization and $4.7$5.9 million for stock-based compensation. The Diagnostics segment operating loss also included a non-cash pre-tax benefit of $1.5 million$36,000 associated with the change in the fair value of acquisition-related contingent consideration. This is in comparison to an $1.0 million benefit recorded in the first half of 2021.
Molecular Solutions Segment
The gross profit percentagemargin for the Molecular Solutions segment was 66%47% for the ninesix months ended SeptemberJune 30, 20212022 compared to 69%68% for the ninesix months ended SeptemberJune 30, 2020.2021. This decrease iswas due to an increase in reserves for excess inventory as result of a forecasted decline in demand and a less favorable product mix associated with increased sales of lower gross profit percentage product and increased costmix.s at our third party contract manufacturers.
Research and development expenses increased 11% to $7.9$5.7 million for the ninesix months ended SeptemberJune 30, 20212022 from $7.1$5.1 million for the ninesix months ended SeptemberJune 30, 20202021 due to increasedhigher staffing and consulting costs. Sales and marketing expenses increased 31%18% to $12.1$8.5 million for the ninesix months ended SeptemberJune 30, 20212022 from $9.2$7.2 million for the ninesix months ended SeptemberJune 30, 20202021 due to higher staffing costs related to increased head count, increased consulting costsexpense associated with business strategy planning, and an increase in our reserve for uncollectible accountstravel costs as COVID-19 restrictions are lifted. These increases in expenses were partially offset by lower amortization expense associated with an intangible asset that was fully amortized at the end of 2021.. General and administrative expenses increased 24%58% to $12.1 million for the ninesix months ended SeptemberJune 30, 20212022 from $9.7$7.6 million for the ninesix months ended SeptemberJune 30, 20202021 due to increased intercompany servicelegal fees allocated fromand staffing costs.
Operating expenses for the DiagnosticsMolecular segment estimated penalties incurred on delinquent sales tax filings that were not recognized inalso includes an impairment charge of $2.0 million for the prior year period, higher staffing costs,six months ended June 30, 2022 associated with two idle manufacturing lines for which there are no projected cash flow and increased legal fees.minimal resale or salvage value.
All of the above contributed to the Molecular Solutions segment’s operating incomeloss of $42.0$5.7 million for the ninesix months ended SeptemberJune 30, 2021,2022, which included $5.5the non-cash impairment charge of $2.0 million, $3.8 million for depreciation and amortization and $496,000$924,000 for stock-based compensation.
CONSOLIDATED INCOME TAXES
We continue to believe the full valuation allowance established against our total U.S. deferred tax asset is appropriate as the facts and circumstances necessitating the allowance have not changed. For the ninesix months ended SeptemberJune 30, 2021,2022, we recorded U.S. state tax expense of $13,000$400,000 compared to $612,000$115,000 of state income tax benefitexpense for the ninesix months ended SeptemberJune 30, 2020.2021. Additionally, in the first half of 2022, we recorded approximately $1.7 million of withholding taxes due to the Canada Revenue Agency associated with our repatriation of $65.0 million of cash from Canada to the United States. For the ninesix months ended SeptemberJune 30, 2021,2022, we recorded foreign tax expense of $12.2 million$665,000 compared to foreign tax expense of $6.3$10.0 million for the ninesix months ended SeptemberJune 30, 2020. The2021. This overall increasedecrease in foreign tax expense is largely a result of the increasedecrease in income before taxes generated by our Canadian subsidiary.
27
Liquidity and Capital Resources
|
| September 30, |
|
| December 31, |
|
| June 30, |
|
| December 31, |
| ||||
|
| 2021 |
| 2020 |
|
| 2022 |
|
| 2021 |
| |||||
|
| (In thousands) |
|
| (In thousands) |
| ||||||||||
Cash and cash equivalents |
| $ | 134,962 |
|
| $ | 160,802 |
|
| $ | 66,159 |
|
| $ | 116,762 |
|
Available for sale securities |
| 67,336 |
|
|
| 96,317 |
|
|
| 29,625 |
|
|
| 53,288 |
| |
Working capital |
| 235,060 |
|
|
| 242,404 |
|
|
| 201,820 |
|
|
| 220,367 |
|
Our cash and cash equivalents and available-for-sale securities decreased to $202.3$95.8 million at SeptemberJune 30, 20212022 from $257.1$170.1 million at December 31, 2020.2021. Our working capital decreased to $235.1$201.8 million at SeptemberJune 30, 20212022 from $242.4$220.4 million at December 31, 2020.2021.
During the ninesix months ended SeptemberJune 30, 2021,2022, net cash used in operating activities was $22.6$45.5 million. Our net loss of $12.6$38.8 million included non-cash charges forof $10.5 million associated with impairment charges taken against idle manufacturing lines and goodwill, depreciation and amortization expense of $8.5$7.5 million, stock-based compensation expense of $5.2$6.8 million, a provision for doubtful accountsan inventory reserve of $1.2$2.0 million, and other non-cash expense of $105,000. Operating activities also included a benefit for the change in the estimated fair value of acquisition-related contingent consideration of $1.5 million and a $142,000 contingent consideration payment representing the excess of the total contingent consideration payment made during the nine months ended September 30, 2021 over the fair value of the liability estimated at the time of acquisition. Sources of cash generated from$1.2 million. Cash used to fund our working capital accounts included an increase in inventory of $20.4 million to meet
29
anticipated demand to support COVID-19 testing program, an increase in accounts receivable of $18.6 million largely associated with product shipped to the U.S. government, a $2.8$4.1 million increase in prepaid expenses and other assets associated with tax installments made to the Canadian Revenue Agency and a $2.9 million decrease in accrued expenses and other liabilities largely due to payment of our 2021 bonuses and severance payments to our former CEO. Offsetting these uses of cash was a $11.9 million increase in accounts payable due to the timing of invoices received and payments made and an increase in accrued expenses and other liabilities of $982,000 made.associated with increased accruals for professional fees and higher sales tax payable. Offsetting these sources of cash were an increase in inventory of $21.7 million to meet anticipated demand to support COVID-19 testing programs, an increase in accounts receivable of $2.1 million due to orders placed late in the quarter, an increase in prepaid expenses and other assets of $1.9 million due to prepayments made on a manufacturing contract and a decrease in deferred revenue of $1.3 million due to the recognition of revenue from customer prepayments.
Net cash provided byused in investing activities was $776,000$2.3 million for the ninesix months ended SeptemberJune 30, 2021,2022, which reflects proceeds from the maturities and redemptions of investments of $53.8 million$23.0 million. This was offset by $27.5$25.4 million used to acquire property and equipment largely to increase our manufacturing capacity and $25.5 million used to purchase investments.capacity.
Net cash used in financing activities was $3.1$2.5 million for the ninesix months ended SeptemberJune 30, 2021,2022, which reflects $1.9is largely comprised of $2.0 million used for the repurchase of common stock to satisfy withholding taxes related to the vesting of restricted shares awarded to our employees, payments of lease liabilities of $1.1 million and $264,000 used for payment of our contingent consideration obligation, partially offset by proceeds from stock option exercises of $247,000.employees.
We expect current balances of cash and cash equivalents and available-for-sale securities to be sufficient to fund our current and foreseeable operating and capital needs.needs as well as those arising over the next twelve months. Our cash requirements, however, may vary materially from those now planned due to many factors, including, but not limited to, the timing of reimbursement under our $109 million DOD contract, the scope and timing of future strategic acquisitions, the progress of our research and development programs, the scope and results of clinical testing, the cost of any future litigation, the magnitude of capital expenditures, including continued investment to expand our capacity to manufacture products for COVID-19 testing, changes in existing and potential relationships with business partners, the timing and cost of obtaining regulatory approvals, the timing and cost of future stock purchases, the costs involved in obtaining and enforcing patents, proprietary rights and any necessary licenses, the cost and timing of expansion of sales and marketing activities, market acceptance of new products, competing technological and market developments, the impact of the current economic environment and other factors. In addition, $129.2$74.7 million or 64%78% of our $202.3$95.8 million in cash, cash equivalents and available-for-sale securities belongs to our Canadian subsidiary. RepatriationIn the first quarter of such2022, we repatriated $65.0 million of cash from Canada into the United States exceeding certain levelsand incurred approximately $1.7 million of Canadian withholding tax. Further repatriation of cash from Canada into the United States could have additional adverse tax consequences. It is our intention going forward to continue to permanently reinvest the historical undistributed earnings of our foreign subsidiaries.
A summary of our obligations to make future payments under contracts existing at December 31, 20202021 is included in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, of our Annual Report on Form 10-K for the year ended December 31, 2020.2021. As of SeptemberJune 30, 2021, except as described in note 11 within the notes to the consolidated financial statements,2022, there were no significant changes to this information.
Critical Accounting Policies and Estimates
This Management’s Discussion and Analysis of Financial Condition and Results of Operations discusses our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, we evaluate our judgments and estimates, including those related to the bad debts, customer sales returns, inventories, intangible assets, income taxes, revenue recognition, performance-based compensation, contingencies and litigation. We base our judgments and estimates on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
28
A more detailed review of our critical accounting policies is contained in our Annual Report on Form 10-K for the year ended December 31, 20202021 filed with the SEC. During the first nine months of 2021, there wereExcept as presented below, no material changes have been made to oursuch critical accounting policies.policies during the six months ended June 30, 2022.
Goodwill
Goodwill is not amortized, but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment and If it is determined that it is more likely than not that the fair value does not exceed the carrying amount, then a quantitative test is performed. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount. An impairment charge is recognized in the amount by which the carrying amount exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit.
The process of evaluating the potential impairment of goodwill is highly subjective and requires significant judgment, including the identification of reporting units, qualitative evaluation of events and circumstances to determine if it is more likely than not that an impairment exists, and, if necessary, the estimation of the fair value of the applicable reporting unit.
30
.
Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We do not hold any amounts of derivative financial instruments or derivative commodity instruments and, accordingly, we have no material derivative risk to report under this Item.
As of SeptemberJune 30, 2021,2022, we did not have any foreign currency exchange contracts or purchase currency options to hedge local currency cash flows. Sales denominated in foreign currencies comprised 5.2%3.5% of our total revenues for the ninesix months ended SeptemberJune 30, 2021.2022. We do have foreign currency exchange risk related to our operating subsidiaries in Canada and in Belgium. The principal foreign currencies in which we conduct business are the Canadian dollar and the Euro. Fluctuations in the exchange rate between the U.S. dollar and these foreign currencies could affect year-to-year comparability of operating results and cash flows. Our foreign subsidiaries had net assets, subject to translation, of $194.2$130.9 million in U.S. Dollars, which are included in the Company’s consolidated balance sheet as of SeptemberJune 30, 2021.2022. A 10% unfavorable change in the Canadian-to-U.S. dollar and Euro-to-U.S. dollar exchange rates would have decreased our comprehensive income by approximately $16.8$13.1 million in the ninesix months ended SeptemberJune 30, 2021.2022.
Item 4. CONTROLS AND PROCEDURES
(a) Evaluation of Disclosure Controls and Procedures. The Company’s management, with the participation of the Company’s Chief Executive Officer and Interim Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) as of SeptemberJune 30, 2021.2022. Based on that evaluation, the Company’s management, including such officers, concluded that the Company’s disclosure controls and procedures were effective as of SeptemberJune 30, 20212022 to provide reasonable assurance that material information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934 was accumulated and communicated to the Company’s management, including the Chief Executive Officer and Interim Chief Financial Officer, to allow timely decisions regarding required disclosure and was recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission.
(b) Changes in Internal Control Over Financial Reporting. There was no change in the Company’s internal control over financial reporting that occurred during the three months ended SeptemberJune 30, 20212022 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. LEGAL PROCEEDINGS
From time to time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, based upon the advice of counsel, the outcomes of such actions are not expected, individually or in the aggregate, to have a material adverse effect on our future financial position or results of operations.
Spectrum Patent Litigation
In March 2021, we filed a complaint against Spectrum Solutions, LLC ("Spectrum") in the United States District Court for the Southern District of California alleging that certain saliva collection devices manufactured and sold by Spectrum infringe a patent held by DNAG. Spectrum has filed an answer to the initial complaint, asserting that its device does not infringe our patent and that our patent is invalid. In August 2021, we amended our complaint to add a second patent to this litigation. Spectrum responded to our amended complaint and asserted counterclaims for inequitable conduct and antitrust violations with respect to one of the patents in the litigation. We believe Spectrum's counterclaims are without merit and weDNAG filed a motion to dismiss both claimsSpectrum’s counterclaims in October 2021.2021, which was denied by the Court on March 30, 2022. On April 8, 2022, the Court assigned a new judge to preside over the matter, which vacated all dates for the trial. We are seeking injunctive relief and damages in this matter.await new dates to be set by the Court.
Item 1A. RISK FACTORS
The risk factors set forth in this report update should be read together withThere have been no material changes to the risk factors discusseddisclosed in Item 1A, ofentitled “Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2020.2021, other than as set forth below.
Customer Concentration Creates Risk for Our U.S. Government Contracts Require Compliance With Numerous LawsBusiness.
One non-commercial customer accounted for 56% and Increases Our Risk39% of net consolidated revenues for the three and Liability.six months ended June 30, 2022. We
From time to time, we receive funding from the U.S. government and we sell some of our products to the federal government. Historically, we have sold a number of our products to the government under contracts with the General Services Administration and the Veterans
2931
Administration. During the third quarter of 2021, we entered into a contract with the Defense Logistics Agency ("DLA") for the procurement of our InteliSwabTM COVID-19 Rapid Test for over-the-counter use, with an estimated value of $205 million. During the same quarter, we entered into a contract with the Biomedical Advanced Research Development Authority to provide us with up to $13.6 million in funding to obtain FDA 510(k) clearance and Clinical Laboratory Improvement Amendments ("CLIA") waiver for our InteliSwabTM COVID-19 Rapid Test. In September 2021, we entered into a contract with the U.S. Department of Defense, in coordination with the Department of Health and Human Services, for $109 million in funding to build additional manufacturing capacity in the United States for our InteliSwabTM COVID-19 Rapid Test.
As a result of our U.S. government funding and productexpect that sales to the U.S. government, we must comply with laws and regulations relatinglarge non-commercial customer will continue to the award, administration and performance of U.S. government contracts. U.S. government contracts typically containbe a number of extraordinary provisions that would not typically be found in commercial contracts and which may create a disadvantage and additional riskssignificant contributor to us as compared to competitors that do not rely on government contracts. For example, the government has the right to terminate one or more of these contracts at its convenience even if we have not defaulted in anyour net consolidated revenue. Certain parts of our obligations.
Asbusiness may continue to have a U.S. government contractor, we are subjecthigh customer concentration and depend disproportionately on a few large customers. To the extent that such a large customers fail to increased risks of investigation, criminal prosecution and other legal actions and liabilities to which purely private sector companies are not. The results of any such actions could adversely impact ourmeet their purchase commitments, change their ordering patterns or business and have an adverse effect on our consolidated financial performance. The U.S. government recently announced that federal contractors who are party to a broad range of contracts with the government must require their employees to be vaccinated against the COVID-19 virus and comply with current masking and social distancing safety procedures. If we become subject to these requirements, we could experience a loss of personnel and difficulty in recruiting new employees, each of which could adversely affect our business.
A violation of specific laws and regulations could result in the imposition of fines and penalties or the termination of our contracts, as well as suspension or debarment. The suspension or debarment in any particular case may be limited to the facility, contract or subsidiary involved in the violation or could be applied to our entire enterprise in certain severe circumstances. Even a narrow scope suspension or debarment could result in negative publicity that could adversely affect our ability to renew contracts and to secure new contracts, both with the U.S. government and private customers, which could materially and adversely affect our business and results of operations. Fines and penalties could be imposed for failing to follow procurement integrity and bidding rules, employing improper billing practicesstrategies, or otherwise failing to follow rules relating to billing on cost-plus contracts, receivingreduce their purchases or paying kickbacks, or filing false claims, among other potential violations. In addition, we could suffer serious reputational harm and the value of our common stock could be negatively affected if allegations of impropriety related to such contracts are made against us.
Our Inability to Manufacture Products in Accordance With Applicable Specifications, Performance Standards or Quality Requirements Could Adversely Affect Our Business.
The materials and processes used to manufacture our products must meet detailed specifications, performance standards and quality requirements to ensure our products will perform in accordance with their label claims, our customers’ expectations and applicable regulatory requirements. As a result, our products and the materials used in their manufacture or assembly undergo regular inspections and quality testing. Factors such as defective materials or processes, mechanical failures, human errors, environmental conditions, changes in materials or production methods, and other events or conditions could causestop purchasing our products, or if we experience difficulty in meeting the materials used to produce or assemblehigh demand by these larger customers for our products, to fail inspections and quality testing or otherwise not perform in accordance with our label claims or the expectations of our customers.
Any failure or delay in our ability to meet the applicable specifications, performance standards, quality requirements or customer expectations could adversely affect our ability to manufacture and sell our products or comply with regulatory requirements. These events could, in turn, adversely affect our revenues and results of operations.
In June 2021, we received FDA Emergency Use Authorization for our InteliSwabTM COVID-19 Rapid Test. Although there has been significant demand for this product, we have experienced difficulties manufacturing our test in accordance with applicable specifications. We believe these difficulties are the result of variability in certain incoming raw materials used in the product and certain processing steps. As a result, we have not been able to meet the demand for our product and sales of our InteliSwabTM COVID-19 Rapid Test have been negatively impacted. If we are not able to resolve the manufacturing difficulties in a timely manner, or at all, our revenues and results of operations may not meet expectations and could be adversely affected.
Our Business Results Depend on our Ability to Manage Disruptions in our Domestic and Global Supply Chains and Distribution Channels.
Our ability to meet our customers needs and achieve our financial objectives depends on our ability to maintain key manufacturing, supply and distribution arrangements. The loss or disruption of such manufacturing and supply arrangements could, in the future, interrupt our ability to obtain necessary raw materials and manufacture our products. Such disruptions could result from labor disputes, financial liquidity, natural disasters, extreme weather conditions, public health emergencies and pandemics, supply constraints and general economic and political conditions that could limit the ability of our suppliers to timely provide us with raw materials and components and distribute our products in a timely manner
30
in accordance with applicable quality requirements. Disruptions in the global supply chain could also delay or preclude the ability of our distributors to sell and deliver our products to customers. Recently, the global supply chain has experienced significant disruptions caused by the COVID-19 pandemic, resulting in shortages of labor and equipment. These conditions, if not mitigated or remedied in a timely manner, could delay or preclude delivery of raw materials needed to manufacture our products or delivery of our products to customers, particularly in international markets. This in turn could have an adverse impact on our business, financial condition, results of operations or cash flows.
Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Period |
| Total number of |
|
|
| Average price |
|
| Total number of |
|
| Maximum number (or |
| ||||
July 1, 2021 - July 31, 2021 |
|
| 594 |
| (3) |
| $ | 10.40 |
|
|
| — |
|
|
| 11,984,720 |
|
August 1, 2021 - August 31, 2021 |
|
| 3,673 |
| (3) |
|
| 11.15 |
|
|
| — |
|
|
| 11,984,720 |
|
September 1, 2021 - September 30, 2021 |
|
| — |
|
|
|
| — |
|
|
| — |
|
|
| 11,984,720 |
|
|
|
| 4,267 |
|
|
|
|
|
|
| — |
|
|
|
|
Period |
| Total number of |
|
|
| Average price |
|
| Total number of |
|
| Maximum number (or |
| ||||
April 1, 2022 - April 30, 2022 |
|
| 107,316 |
| (3) |
| $ | 7.08 |
|
|
| — |
|
|
| 11,984,720 |
|
May 1, 2022 - May 31, 2022 |
|
| 21,979 |
| (3) |
|
| 5.17 |
|
|
| — |
|
|
| 11,984,720 |
|
June 1, 2022 - June 30, 2022 |
|
| 12,311 |
|
|
|
| 3.83 |
|
|
| — |
|
|
| 11,984,720 |
|
|
|
| 141,606 |
|
|
|
|
|
|
| — |
|
|
|
|
Item 3. DEFAULTS UPON SENIOR SECURITIES
None
Item 4. MINE SAFETY DISCLOSURES
Not applicable
Item 5. OTHER INFORMATION
None
3132
Item 6. EXHIBITS
Exhibit Number |
| Exhibit |
10.1*
|
| |
| ||
| ||
| ||
| ||
| ||
31.1* | ||
31.2* | ||
32.1*+ | ||
32.2*+ | ||
101.INS | Inline XBRL Instance Document – the Instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |
101.SCH | Inline XBRL Taxonomy Extension Schema Document | |
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
101.LAB | Inline XBRL Taxonomy Extension Labels Linkbase Document | |
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
Exhibit 104 | Cover Page from the Company’s Quarterly Report on Form 10-Q for the Quarter Ended June 30, 2021 has been formatted in Inline XBRL |
*Filed herewith
** Management contract or compensatory plan or arrangement.
+This certification is deemed not filed for purposes of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
32
33
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
ORASURE TECHNOLOGIES, INC. | |||
/s/ Scott Gleason | |||
Date: | Scott Gleason | ||
| |||
(Principal Financial Officer) | |||
/s/Michele M. Miller | |||
Date: | Michele M. Miller | ||
Senior Vice President, | |||
(Principal Accounting Officer) |
3334